CN103113359A - Silibinin diunsymsuccinate and pharmaceutical salt thereof - Google Patents
Silibinin diunsymsuccinate and pharmaceutical salt thereof Download PDFInfo
- Publication number
- CN103113359A CN103113359A CN2013100570655A CN201310057065A CN103113359A CN 103113359 A CN103113359 A CN 103113359A CN 2013100570655 A CN2013100570655 A CN 2013100570655A CN 201310057065 A CN201310057065 A CN 201310057065A CN 103113359 A CN103113359 A CN 103113359A
- Authority
- CN
- China
- Prior art keywords
- peak
- chromatographic
- retention time
- solution
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- SEBFKMXJBCUCAI-HKTJVKLFSA-N silibinin Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-HKTJVKLFSA-N 0.000 title claims abstract description 162
- SEBFKMXJBCUCAI-UHFFFAOYSA-N NSC 227190 Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC=C(C=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 SEBFKMXJBCUCAI-UHFFFAOYSA-N 0.000 title claims abstract description 158
- 235000014899 silybin Nutrition 0.000 title claims abstract description 156
- 229950000628 silibinin Drugs 0.000 title claims abstract description 117
- 150000003839 salts Chemical class 0.000 title claims abstract description 42
- 150000001875 compounds Chemical class 0.000 claims abstract description 263
- 238000000034 method Methods 0.000 claims abstract description 56
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 24
- 239000001257 hydrogen Substances 0.000 claims abstract description 18
- 229910021645 metal ion Inorganic materials 0.000 claims abstract description 17
- 230000014759 maintenance of location Effects 0.000 claims description 283
- 239000000243 solution Substances 0.000 claims description 231
- 239000000047 product Substances 0.000 claims description 179
- 238000004811 liquid chromatography Methods 0.000 claims description 106
- 238000012360 testing method Methods 0.000 claims description 98
- 239000007924 injection Substances 0.000 claims description 94
- 238000002347 injection Methods 0.000 claims description 94
- 239000008194 pharmaceutical composition Substances 0.000 claims description 81
- 239000011550 stock solution Substances 0.000 claims description 78
- 238000002360 preparation method Methods 0.000 claims description 67
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 63
- 239000000463 material Substances 0.000 claims description 60
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 48
- 238000001228 spectrum Methods 0.000 claims description 48
- OKKJLVBELUTLKV-UHFFFAOYSA-N methyl alcohol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 47
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 44
- 239000003814 drug Substances 0.000 claims description 43
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 42
- FDQAOULAVFHKBX-UHFFFAOYSA-N Isosilybin A Natural products C1=C(O)C(OC)=CC(C2C(OC3=CC(=CC=C3O2)C2C(C(=O)C3=C(O)C=C(O)C=C3O2)O)CO)=C1 FDQAOULAVFHKBX-UHFFFAOYSA-N 0.000 claims description 39
- VLGROHBNWZUINI-UHFFFAOYSA-N Silybin Natural products COc1cc(ccc1O)C2OC3C=C(C=CC3OC2CO)C4Oc5cc(O)cc(O)c5C(=O)C4O VLGROHBNWZUINI-UHFFFAOYSA-N 0.000 claims description 39
- 229940043175 silybin Drugs 0.000 claims description 39
- 238000012163 sequencing technique Methods 0.000 claims description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 38
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 37
- 238000001514 detection method Methods 0.000 claims description 35
- 239000000203 mixture Substances 0.000 claims description 35
- 239000003795 chemical substances by application Substances 0.000 claims description 33
- 238000006243 chemical reaction Methods 0.000 claims description 31
- 150000002148 esters Chemical class 0.000 claims description 29
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 26
- 210000004185 liver Anatomy 0.000 claims description 26
- 239000010410 layer Substances 0.000 claims description 25
- 239000000377 silicon dioxide Substances 0.000 claims description 24
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 22
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 22
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 22
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 claims description 22
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 22
- 239000007787 solid Substances 0.000 claims description 21
- 229940079593 drug Drugs 0.000 claims description 20
- 239000012535 impurity Substances 0.000 claims description 19
- 238000003756 stirring Methods 0.000 claims description 19
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 18
- 238000012856 packing Methods 0.000 claims description 17
- -1 alkali metal salt Chemical class 0.000 claims description 16
- 229910052799 carbon Inorganic materials 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 14
- 208000005374 Poisoning Diseases 0.000 claims description 14
- 238000003556 assay Methods 0.000 claims description 14
- 231100000572 poisoning Toxicity 0.000 claims description 14
- 230000000607 poisoning effect Effects 0.000 claims description 14
- 208000019423 liver disease Diseases 0.000 claims description 13
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 13
- 208000004930 Fatty Liver Diseases 0.000 claims description 12
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 12
- 229960004756 ethanol Drugs 0.000 claims description 12
- 208000010706 fatty liver disease Diseases 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 11
- 239000000470 constituent Substances 0.000 claims description 11
- 230000035945 sensitivity Effects 0.000 claims description 11
- 230000001154 acute effect Effects 0.000 claims description 10
- 238000007906 compression Methods 0.000 claims description 10
- 230000006835 compression Effects 0.000 claims description 10
- 239000012044 organic layer Substances 0.000 claims description 10
- 238000004262 preparative liquid chromatography Methods 0.000 claims description 10
- 239000000523 sample Substances 0.000 claims description 10
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- 230000004064 dysfunction Effects 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 8
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 7
- 230000006872 improvement Effects 0.000 claims description 7
- 239000003960 organic solvent Substances 0.000 claims description 7
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 208000006454 hepatitis Diseases 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 230000001476 alcoholic effect Effects 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 5
- 230000007062 hydrolysis Effects 0.000 claims description 5
- 238000006460 hydrolysis reaction Methods 0.000 claims description 5
- 230000003301 hydrolyzing effect Effects 0.000 claims description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- 230000007935 neutral effect Effects 0.000 claims description 5
- 230000036961 partial effect Effects 0.000 claims description 5
- 238000002390 rotary evaporation Methods 0.000 claims description 5
- 238000005070 sampling Methods 0.000 claims description 5
- RINCXYDBBGOEEQ-UHFFFAOYSA-N succinic anhydride Chemical compound O=C1CCC(=O)O1 RINCXYDBBGOEEQ-UHFFFAOYSA-N 0.000 claims description 5
- 238000001291 vacuum drying Methods 0.000 claims description 5
- 239000002699 waste material Substances 0.000 claims description 5
- 241000948470 Amanita phalloides Species 0.000 claims description 4
- 206010008909 Chronic Hepatitis Diseases 0.000 claims description 4
- 206010016654 Fibrosis Diseases 0.000 claims description 4
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical group [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 claims description 4
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical group [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 claims description 4
- 230000007882 cirrhosis Effects 0.000 claims description 4
- 230000002440 hepatic effect Effects 0.000 claims description 4
- 229910001414 potassium ion Inorganic materials 0.000 claims description 4
- 229910001415 sodium ion Inorganic materials 0.000 claims description 4
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical group [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 3
- 208000008964 Chemical and Drug Induced Liver Injury Diseases 0.000 claims description 3
- HBBGRARXTFLTSG-UHFFFAOYSA-N Lithium ion Chemical group [Li+] HBBGRARXTFLTSG-UHFFFAOYSA-N 0.000 claims description 3
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical group [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 claims description 3
- 229910001424 calcium ion Chemical group 0.000 claims description 3
- 229910001416 lithium ion Inorganic materials 0.000 claims description 3
- 229910001425 magnesium ion Inorganic materials 0.000 claims description 3
- 229910052783 alkali metal Inorganic materials 0.000 claims description 2
- 150000008044 alkali metal hydroxides Chemical class 0.000 claims description 2
- 229910001413 alkali metal ion Inorganic materials 0.000 claims description 2
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 claims description 2
- 229910001420 alkaline earth metal ion Inorganic materials 0.000 claims description 2
- 239000000126 substance Substances 0.000 abstract description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 230000008092 positive effect Effects 0.000 abstract 1
- 229940090044 injection Drugs 0.000 description 71
- 230000003187 abdominal effect Effects 0.000 description 22
- 230000000694 effects Effects 0.000 description 21
- 159000000000 sodium salts Chemical group 0.000 description 18
- YIDLJQVKFQDISS-DSGKQNAUSA-L disodium;4-[[(2r,3r)-6-[(2r,3r)-3-(3-carboxylatopropanoyloxy)-5,7-dihydroxy-4-oxo-2,3-dihydrochromen-2-yl]-3-(4-hydroxy-3-methoxyphenyl)-2,3-dihydro-1,4-benzodioxin-2-yl]methoxy]-4-oxobutanoate Chemical class [Na+].[Na+].C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)OC(=O)CCC([O-])=O)COC(=O)CCC([O-])=O)=C1 YIDLJQVKFQDISS-DSGKQNAUSA-L 0.000 description 17
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 108010006464 Hemolysin Proteins Proteins 0.000 description 14
- 239000003228 hemolysin Substances 0.000 description 14
- 239000000843 powder Substances 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 239000002904 solvent Substances 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 11
- 241000134916 Amanita Species 0.000 description 10
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 239000002775 capsule Substances 0.000 description 9
- 239000003921 oil Substances 0.000 description 9
- 235000019198 oils Nutrition 0.000 description 9
- 238000010521 absorption reaction Methods 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 229910052760 oxygen Inorganic materials 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 239000002502 liposome Substances 0.000 description 7
- 238000011084 recovery Methods 0.000 description 7
- 239000012925 reference material Substances 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 241000700721 Hepatitis B virus Species 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- 230000034994 death Effects 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 241000222336 Ganoderma Species 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 5
- 239000000829 suppository Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 4
- 206010067125 Liver injury Diseases 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 229940014259 gelatin Drugs 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 231100000753 hepatic injury Toxicity 0.000 description 4
- 238000007689 inspection Methods 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000002574 poison Substances 0.000 description 4
- 231100000614 poison Toxicity 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- 241000272814 Anser sp. Species 0.000 description 3
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 235000010419 agar Nutrition 0.000 description 3
- 210000005252 bulbus oculi Anatomy 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000008297 liquid dosage form Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 150000003904 phospholipids Chemical class 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000000582 semen Anatomy 0.000 description 3
- OVYTZAASVAZITK-UHFFFAOYSA-M sodium;ethanol;hydroxide Chemical compound [OH-].[Na+].CCO OVYTZAASVAZITK-UHFFFAOYSA-M 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 231100000111 LD50 Toxicity 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- 235000013539 calcium stearate Nutrition 0.000 description 2
- 239000008116 calcium stearate Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000013375 chromatographic separation Methods 0.000 description 2
- 231100000012 chronic liver injury Toxicity 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 125000004185 ester group Chemical group 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 231100000283 hepatitis Toxicity 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 229940102223 injectable solution Drugs 0.000 description 2
- 231100000636 lethal dose Toxicity 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 238000005502 peroxidation Methods 0.000 description 2
- 238000005220 pharmaceutical analysis Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- HKOOXMFOFWEVGF-UHFFFAOYSA-N phenylhydrazine Chemical compound NNC1=CC=CC=C1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 description 2
- 229940067157 phenylhydrazine Drugs 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 229960004245 silymarin Drugs 0.000 description 2
- 235000017700 silymarin Nutrition 0.000 description 2
- 239000008354 sodium chloride injection Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 231100000167 toxic agent Toxicity 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- AYIRNRDRBQJXIF-NXEZZACHSA-N (-)-Florfenicol Chemical compound CS(=O)(=O)C1=CC=C([C@@H](O)[C@@H](CF)NC(=O)C(Cl)Cl)C=C1 AYIRNRDRBQJXIF-NXEZZACHSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 description 1
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
- JXTPWYSSFFOISU-BMSWWXRLSA-N 4-[[(2r,3r)-6-[(2r,3r)-3-(3-carboxypropanoyloxy)-5,7-dihydroxy-4-oxo-2,3-dihydrochromen-2-yl]-3-(4-hydroxy-3-methoxyphenyl)-2,3-dihydro-1,4-benzodioxin-2-yl]methoxy]-4-oxobutanoic acid Chemical compound C1=C(O)C(OC)=CC([C@@H]2[C@H](OC3=CC=C(C=C3O2)[C@@H]2[C@H](C(=O)C3=C(O)C=C(O)C=C3O2)OC(=O)CCC(O)=O)COC(=O)CCC(O)=O)=C1 JXTPWYSSFFOISU-BMSWWXRLSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241000948559 Amanita fuliginea Species 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 0 C[C@](*)([C@@](C)(c1ccc2OC(*)C(c(cc3)cc(*)c3O)Oc2c1)Oc1c2c(O)cc(O)c1)C2=O Chemical compound C[C@](*)([C@@](C)(c1ccc2OC(*)C(c(cc3)cc(*)c3O)Oc2c1)Oc1c2c(O)cc(O)c1)C2=O 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 244000192528 Chrysanthemum parthenium Species 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 238000010268 HPLC based assay Methods 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229910052777 Praseodymium Inorganic materials 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 240000006474 Theobroma bicolor Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N butyl alcohol Substances CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- QZHPTGXQGDFGEN-UHFFFAOYSA-N chromene Chemical group C1=CC=C2C=C[CH]OC2=C1 QZHPTGXQGDFGEN-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 229920006237 degradable polymer Polymers 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000007046 ethoxylation reaction Methods 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229960003760 florfenicol Drugs 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 239000000451 gelidium spp. gum Substances 0.000 description 1
- 229940093181 glucose injection Drugs 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 206010019692 hepatic necrosis Diseases 0.000 description 1
- 230000007866 hepatic necrosis Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 231100000334 hepatotoxic Toxicity 0.000 description 1
- 230000003082 hepatotoxic effect Effects 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 239000000976 ink Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 150000002527 isonitriles Chemical class 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
- 229960001627 lamivudine Drugs 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000001853 liver microsome Anatomy 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 108010033145 microsomal ethanol-oxidizing system Proteins 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- UFWIBTONFRDIAS-UHFFFAOYSA-N naphthalene-acid Natural products C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000000668 oral spray Substances 0.000 description 1
- 229940041678 oral spray Drugs 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- LYKMMUBOEFYJQG-UHFFFAOYSA-N piperoxan Chemical compound C1OC2=CC=CC=C2OC1CN1CCCCC1 LYKMMUBOEFYJQG-UHFFFAOYSA-N 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- PUDIUYLPXJFUGB-UHFFFAOYSA-N praseodymium atom Chemical compound [Pr] PUDIUYLPXJFUGB-UHFFFAOYSA-N 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012772 sequence design Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000011257 shell material Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229960001866 silicon dioxide Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002594 sorbent Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960005137 succinic acid Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
Images
Abstract
The invention relates to a silibinin diunsymsuccinate and a pharmaceutical salt thereof. Specifically, the invention provides a compound which is a combination of four isomers of a compound expressed as formula I, wherein various Xs respectively independently represent hydrogen or metal ions. Furthermore, the invention provides a method and a pharmaceutical use of the compound. The compound disclosed by the invention has positive effects on biological and/or physical and/or chemical aspects.
Description
Technical field
The invention belongs to medical technical field, relate to the silybin bis-bias succinate and the pharmaceutical salts thereof that are used for the treatment of hepatopathy, with and preparation method thereof, also relate to a kind of pharmaceutical composition that comprises this silybin bis-bias succinate or its pharmaceutical salts.Pharmaceutical composition of the present invention has the good nature of expectation.
Background technology
In recent years, along with the raising of people's living standard and the variation of dietary structure, China's pathogenesis of fatty liver rate oneself near the hepatitis B virus carrying rate, and be obvious ascendant trend.Wherein, the male sex of 30～40 years old is " main force " in Patients with Fatty Liver main forces, substantially accounts for 1/4 of whole Patients with Fatty Liver.According to estimates, present pathogenesis of fatty liver rate is than having increased in the past 30 times of left and right the eighties in 20th century.It is reported that 15% Patients with Fatty Liver can develop into liver cirrhosis, 3% Patients with Fatty Liver can be died from liver failure.So fatty liver is prevented early and treatment has very important significance.
Hepatitis refers to the inflammation due to different pathogeny, and in daily life, viral hepatitis is the most common, and it has, and sickness rate is high, and the course of disease is long, and the patient's condition repeatability is strong, the characteristics that hazardness is large, if in time do not treat, changing is possible of liver cirrhosis and liver cancer.China is again hepatitis country occurred frequently, and according to statistics, China has 1.2 hundred million people of surpassing to infect hepatitis B virus, and chronic viral hepatitis B patient approximately 3,000 ten thousand, 3,800 ten thousand people carries hepatitis C virus, only from hepatitis B virus carriers's numeral, almost accounts for national 1/10th.
At present, although the liver disease drug kind is a lot, there is no a kind of medicine and can really kill hepatitis B virus.Adopt suppressed virus replication or improved symptom, two kinds for the treatment of thinkings of control PD more at present.Although the former can suppress virus replication fast, has the long-term prescription risk.Though hepatitis B virus can be suppressed at lower level (DNA＜10 as hepatopathy first-line drug lamivudine
3Copy/ml), but need long-term prescription (usually 2-3) can not arbitrarily be stopped using, and is not only costly, and long-term prescription directly causes the some patients were hepatitis B virus resistance variant to occur, and the state of an illness is more complicated.Therefore, develop a kind of medicine that can effectively improve the hepatopathy symptom, be fit to long-term prescription and reasonable price, be used for prevention and the treatment of hepatic diseases, meet current national conditions, meet clinical needs.
Silymarin, composite family is the good liver plant of protecting, its main component is silibinin (silybin).Pharmacological evaluation proves, silibinin has the protection liver plasma membrane, improves the effect of liver function, prevents the liver injury due to multiple hepatotoxic agent, promotes liver cell regeneration, is mainly used in treating the diseases such as various acute, chronic hepatitis, first cirrhosis and liver poisoning.
Silibinin is insoluble in water very much, has limited its oral absorption, water-soluble obvious increase after salify.At present, main research concentrates on silybin-N-methylglucamine and silybin-phospholipid complex.The main component that the Seeley guest pacifies sheet is namely silybin meglumine, but still deposits the not high shortcoming of bioavailability.The main component of Silybin is silybin-phosphatidylcholine compound, although by improving the fat-soluble bioavailability that improved to a certain extent, it is water-soluble still relatively poor.
Affect in body the factor of bioavailability and comprise Dosage Form Factors and physiologic factor two aspects: fat-soluble, the water-soluble and pKa value of Dosage Form Factors such as medicine, the difference of the formulation characteristic of medicine (as disintegration, dissolution rate) and some processing condition; Physiologic factor comprises the effect of liquid in gi tract, the transhipment situation of medicine in gi tract, and the surface-area of absorption site and regional flow, the impact of drug metabolism, enteron aisle bacterial strain and some affect the disease of drug absorption etc.Thus, medicine absorbing state in vivo is fat-soluble relevant with medicine itself not only, and water-soluble be also a key parameter.
SDH salt is a kind of derivative of silibinin, it significantly is better than silibinin aspect water-soluble, it is believed that it has the content, the disorder of regulating phospholipid metabolism that reduce serum free fatty acid and triglyceride level, removes oxyradical, suppresses lipid peroxidation, stablize liver plasma membrane, alleviates steatosis, resists the function of hepatic necrosis, can be used for the poisoning treatment of Acute Hepatic that Amanita phalloides causes, also can be used for treatment acute, chronic hepatic injury, and the recovery that is used for the dysfunction of liver that fatty liver and alcoholic liver cause.
CN101302212A discloses preparation method and the purposes of silybin bis-bias succinate and its esters, this it is said effective preparation method be make silibinin in the organic solvent that is fit to the synthetic silibinin fourth diester mono-methyl that obtains of Succinic anhydried reaction, then generate florfenicol sodium succinate salt with the sodium hydroxide reaction in specific medium and realizing.
CN101244041A discloses a kind of for preventing and treat medicine of acute liver damage and preparation method thereof.This patent of invention document is specifically related to the preparation method that a kind of composition is silibinin Soduxin freeze-dried powder, comprises the following steps: (1) is dissolved in the silibinin Soduxin in water for injection, fully stirs into solution; (2) add N.F,USP MANNITOL or lactose to make dissolving in mentioned solution; (3) above-mentioned dissolving is regulated pH7 ~ 9 with the heating activated carbon decolouring and with hydrochloric acid soln or sodium hydroxide solution, filter; (4) filtrate is aseptic subpackaged, lyophilize, and get final product.
Although people are at aspects such as silibinin or derivatives thereof such as silybin bis-bias succinate or its salt of use silibinin product, yet the relative disease that people still expect to have a kind of Innovative method to treat or prevent liver etc. and silibinin or derivatives thereof to treat, particularly expecting has a kind of Innovative method to treat the disease relevant to liver with silybin bis-bias succinate or its salt.
Summary of the invention
The relative disease that the object of the present invention is to provide a kind of Innovative method to treat or prevent liver etc. and silibinin or derivatives thereof to treat particularly expects to have a kind of Innovative method to use silybin bis-bias succinate (also can be described as silibinin disuccinic acid half ester) or its salt to treat the disease relevant to liver.The beat all discovery of the inventor, silybin bis-bias succsinic acid of the present invention or its salt demonstrate the effect of positive biology and/or physics and/or chemical aspect.The present invention is based on this discovery and be accomplished.
Therefore, first aspect present invention provides a kind of compound, and it is the combination of four kinds of isomer of following formula I compound:
Wherein each X represents hydrogen or metal ion independently of one another.
For the present invention, the described compound essence of first aspect present invention is the mixture of four kinds of isomer of formula I compound, therefore strictly, the described compound of first aspect present invention is not single a kind of chemical monomer, but has identical chemical structure but mixture that the isomer of different spaces orientation forms by four kinds.Yet as compound, its main part is several isomer with formula I structure, not can be understood as the inevitable impurity that may exist in the compounds of this invention and do not have a material of formula I structure.
According to the compound of first aspect present invention, wherein said metal ion is alkalimetal ion or alkaline-earth metal ions.
According to the compound of first aspect present invention, wherein X represents hydrogen, sodium ion, potassium ion, lithium ion, magnesium ion or calcium ion independently of one another.In one embodiment, wherein X represents hydrogen, sodium ion, potassium ion, lithium ion, magnesium ion or calcium ion.
According to the compound of first aspect present invention, wherein comprise four kinds of isomer of formula I compound.
According to the compound of first aspect present invention, wherein comprise four kinds of isomer of formula I compound, described isomer is formed by 12-position and 13-position chiral carbon.
According to the compound of first aspect present invention, wherein comprise four kinds of isomer of formula I compound, described four kinds of isomer account for more than 95% of this compound gross weight (for example more than 97%, for example more than 98%, for example more than 99%).From the angle of chemical feedstocks, this parameter usually has identical or approaching implication with chromatographic purity described herein and makes both and be used interchangeably.
Compound according to first aspect present invention, according to high effective liquid chromatography for measuring, it presses out four main chromatographic peaks that the first chromatographic peak (its in the present invention can referred to as E peak or E) and the second chromatographic peak (its in the present invention can referred to as F peak or F) and tertiary color spectrum peak (its in the present invention can referred to as G peak or G) and the 4th chromatographic peak (its in the present invention can referred to as H peak or H) appear being referred to as in peak sequencing successively in color atlas.These four main chromatographic peak E peaks and F peak and G peak and H peak represent the different isomerization body of four formula I compounds in the compounds of this invention.The chromatographic peak that the material of expecting in term " main chromatographic peak " expression color atlas presents, and do not comprise the special formed chromatographic peaks such as material (such as auxiliary material) that add of mobile phase solvent, impurity and other, usually, in color atlas, each " main chromatographic peak " peak area summation accounts for the percentage ratio of whole chromatographic peaks (except auxiliary material, solvent etc.) area summation usually greater than 50%, more generally greater than 75%, more generally greater than 90%, more generally greater than 95%, more generally greater than 98%, for example greater than 98.5%.
compound according to first aspect present invention, according to high effective liquid chromatography for measuring, it presses out four main chromatographic peaks that the first chromatographic peak (its in the present invention can referred to as E peak or E) and the second chromatographic peak (its in the present invention can referred to as F peak or F) and tertiary color spectrum peak (its in the present invention can referred to as G peak or G) and the 4th chromatographic peak (its in the present invention can referred to as H peak or H) appear being referred to as in peak sequencing successively in color atlas, the peak area sum of described the first chromatographic peak and the second chromatographic peak and tertiary color spectrum peak and the 4th chromatographic peak accounts for more than 95% (for example more than 97% of total peak area, for example more than 98%, for example more than 99%) (it also can be described as the chromatographic purity of the compounds of this invention).Whole chromatographic peak area sums that the material of expecting in term " total peak area " expression color atlas and major impurity present, and do not comprise mobile phase solvent and the special formed chromatographic peaks such as material (such as auxiliary material) that add of other.The higher impurity of term " major impurity " expression content, usually refer to peak area greater than expect material chromatographic peak (for example above-mentioned G peak and/or H peak) area 0.0001% (particularly greater than 0.001%, particularly greater than 0.01%, particularly greater than 0.05%) those impurity.
Compound according to first aspect present invention, according to high effective liquid chromatography for measuring, it presses out four main chromatographic peaks that the first chromatographic peak (its in the present invention can referred to as E peak or E) and the second chromatographic peak (its in the present invention can referred to as F peak or F) and tertiary color spectrum peak (its in the present invention can referred to as G peak or G) and the 4th chromatographic peak (its in the present invention can referred to as H peak or H) appear being referred to as in peak sequencing successively in color atlas.In one embodiment, described the second chromatographic peak peak area is that 0.5 ~ 1.5 times of described the first chromatographic peak peak area (also can be expressed as AR (F/E)=0.5 ~ 1.5, for example 0.7 ~ 1.3 times, for example 0.8 ~ 1.2 times, wherein abbreviation " AR " represents area, abbreviation " AR (F/E) " expression F peak-to-peak area also can be regarded as the peak area ratio at two peaks divided by E peak-to-peak area, has similar implication when similar abbreviation is arranged in the present invention).In one embodiment, described tertiary color spectrum peak-to-peak area is 4.5 ~ 13.5 times of described the first chromatographic peak peak area, for example 6.3 ~ 11.7 times, and for example 7.2 ~ 10.8 times.In one embodiment, described the 4th chromatographic peak peak area is 4.5 ~ 13.5 times of described the first chromatographic peak peak area, for example 6.3 ~ 11.7 times, and for example 7.2 ~ 10.8 times.In one embodiment, described E peak, F peak, G peak, H peak peak area ratio is 1:(0.5 ~ 1.5): (4.5 ~ 13.5): (4.5 ~ 13.5); For example described E peak, F peak, G peak, H peak peak area ratio is 1:(0.7 ~ 1.3): (6.3 ~ 11.7): (6.3 ~ 11.7); For example described E peak, F peak, G peak, H peak peak area ratio is 1:(0.8 ~ 1.2): (7.2 ~ 10.8): (7.2 ~ 10.8).The peak area ratio at above-mentioned each peak can obtain with reference to the calculated by peak area at E peak in gained color atlas in " (ii) chromatographic purity and peak area ratio assay method " described herein, F peak, G peak and H peak.
According to the compound of first aspect present invention, wherein said the first chromatographic peak and the second chromatographic peak under described high effective liquid chromatography for measuring condition both resolution greater than 0.8 (for example greater than 1.0, for example greater than 1.2, for example greater than 1.5); And/or, wherein said tertiary color spectrum peak and the 4th chromatographic peak under described high effective liquid chromatography for measuring condition both resolution greater than 1.0 (for example greater than 1.25, for example greater than 1.5, for example greater than 2.0).
Compound according to first aspect present invention, wherein high performance liquid chromatography have make described the first chromatographic peak and the second chromatographic peak can reach resolution greater than 0.8 (for example greater than 1.0, for example greater than 1.2, for example greater than 1.5) the high effective liquid chromatography for measuring condition; And/or wherein high performance liquid chromatography has and makes described tertiary color spectrum peak and the 4th chromatographic peak can reach resolution greater than the high effective liquid chromatography for measuring condition of 1.0 (for example greater than 1.25, for example greater than 1.5, for example greater than 2.0).
compound according to first aspect present invention, according to high effective liquid chromatography for measuring, it presses out four main chromatographic peaks that the first chromatographic peak (its in the present invention can referred to as E peak or E) and the second chromatographic peak (its in the present invention can referred to as F peak or F) and tertiary color spectrum peak (its in the present invention can referred to as G peak or G) and the 4th chromatographic peak (its in the present invention can referred to as H peak or H) appear being referred to as in peak sequencing successively in color atlas, described the first chromatographic peak and the second chromatographic peak resolution both greater than 0.8 (for example greater than 1.0, for example greater than 1.2, for example greater than 1.5), described tertiary color spectrum peak and the 4th chromatographic peak resolution both greater than 1.0 (for example greater than 1.25, for example greater than 1.5, for example greater than 2.0).
According to the compound of first aspect present invention, a representative instance of wherein said high effective liquid chromatography for measuring following by comprising " (i) chromatographic condition and system suitability " mode is carried out:
(i) chromatographic condition and system suitability: be the chromatographic column of weighting agent with octadecylsilane chemically bonded silica, take 0.05mol/L sodium dihydrogen phosphate (with phosphoric acid adjust pH to 4.0)-methyl alcohol (50:50) as moving phase, the detection wavelength is 288nm, and column temperature is 30 ° of C; Get the reference product silibinin appropriate, add moving phase and dissolve and dilute and make the solution that contains silibinin 200 μ g in every 1ml, as the reference product stock solution; Separately get this reference product stock solution and be diluted to the solution of 20 μ g/ml with moving phase, as system suitability solution, get this system suitability solution 20 μ l injection liquid chromatographies, record color atlas; Press out two main chromatographic peaks that A peak and B peak appear being referred to as in peak sequencing successively in this color atlas, the retention time at adjustment A peak is between 6-9min, and the resolution at A peak and B peak should be greater than 1.0 (for example greater than 1.2, for example greater than 1.5, for example greater than 2).Those skilled in the art are known, be the retention time that satisfies above-mentioned A peak and B peak and the requirement of resolution, specification that can be by suitable selection chromatographic column and/or regulate the mode such as flow rate of mobile phase and realize, for example operable column diameter is 4.6mm, the weighting agent granularity can be 5 μ m, its column length can be 15 ~ 30cm (for example approximately 15cm, 20cm, 25cm, 30cm), flow rate of mobile phase can be adjusted in the scope of 0.8 ~ 1.5ml/min, can be easy to realize above-mentioned requirements by regulating column length and flow rate of mobile phase.This is particularly conventional technical ability for the pharmaceutical analysis those skilled in the art for this area.
According to the compound of first aspect present invention, wherein a representative instance following by comprising " (ii) chromatographic purity and the peak area ratio assay method " mode of chromatographic purity and peak area ratio mensuration is carried out:
(ii) chromatographic purity and peak area ratio assay method: get the compounds of this invention appropriate, add moving phase and dissolve and make the solution that concentration is 0.5mg/ml, as need testing solution; Precision measures 1ml, puts in the 100ml measuring bottle, is diluted to scale with moving phase, shakes up, in contrast solution; Adopt the method in (i) chromatographic condition of the present invention and system suitability, get contrast solution 20 μ l injection liquid chromatographies, regulate detection sensitivity, make the peak height of principal constituent H chromatographic peak be about 20% of full range; Precision measures need testing solution and each 20 μ l of contrast solution, and the injection liquid chromatography, record color atlas to 2 times of H chromatographic peak retention time respectively; In the need testing solution color atlas, any chromatographic peak less than 0.05 times of H chromatographic peak area in the contrast solution color atlas is ignored; Record peak area and each impurity peak area at main peak E peak in the need testing solution color atlas, F peak, G peak and H peak, the peak area sum at E peak, F peak, G peak and H peak is divided by whole percentage ratio of peak area sums, be the compounds of this invention chromatographic purity, can calculate respectively to get F peak, G peak and H peak and the peak-to-peak peak area ratio of E with the peak area at F peak, G peak and H peak divided by E peak-to-peak area respectively in addition.
compound according to first aspect present invention, according to high effective liquid chromatography for measuring, take silibinin as reference product, and with the A peak of silibinin as the reference peak that calculates relative retention time, the relative retention time (RRt) of the first chromatographic peak of the compounds of this invention is 1.7 ~ 2.4 (for example 1.8 ~ 2.3, for example 1.85 ~ 2.25, for example 1.9 ~ 2.2, for example 1.95 ~ 2.15), the relative retention time (RRt) of the second chromatographic peak of the compounds of this invention is 1.85 ~ 2.55 (for example 1.95 ~ 2.45, for example 2.0 ~ 2.4, for example 2.05 ~ 2.35, for example 2.1 ~ 2.3), the relative retention time (RRt) at the tertiary color of the compounds of this invention spectrum peak is 2.4 ~ 3.2 (for example 2.45 ~ 3.15, for example 2.5 ~ 3.1, for example 2.55 ~ 3.05, for example 2.6 ~ 3.0), the relative retention time (RRt) of the 4th chromatographic peak of the compounds of this invention is 2.8 ~ 3.6 (for example 2.85 ~ 3.55, for example 2.9 ~ 3.5, for example 2.95 ~ 3.45, for example 3.0 ~ 3.4).
compound according to first aspect present invention, according to high effective liquid chromatography for measuring, take silibinin as reference product, and with the A peak of silibinin as the reference peak that calculates relative retention time, the relative retention time (RRt) of the first chromatographic peak of the compounds of this invention is 1.7 ~ 2.4 (for example 1.8 ~ 2.3, for example 1.85 ~ 2.25, for example 1.9 ~ 2.2, for example 1.95 ~ 2.15), the relative retention time (RRt) of the second chromatographic peak of the compounds of this invention is 1.85 ~ 2.55 (for example 1.95 ~ 2.45, for example 2.0 ~ 2.4, for example 2.05 ~ 2.35, for example 2.1 ~ 2.3), the relative retention time (RRt) at the tertiary color of the compounds of this invention spectrum peak is 2.4 ~ 3.2 (for example 2.45 ~ 3.15, for example 2.5 ~ 3.1, for example 2.55 ~ 3.05, for example 2.6 ~ 3.0), the relative retention time (RRt) of the 4th chromatographic peak of the compounds of this invention is 2.8 ~ 3.6 (for example 2.85 ~ 3.55, for example 2.9 ~ 3.5, for example 2.95 ~ 3.45, for example 3.0 ~ 3.4), described high effective liquid chromatography for measuring relative retention time is by comprising what following mode was carried out:
(i) chromatographic condition and system suitability: be the chromatographic column of weighting agent with octadecylsilane chemically bonded silica, take 0.05mol/L sodium dihydrogen phosphate (with phosphoric acid adjust pH to 4.0)-methyl alcohol (50:50) as moving phase, the detection wavelength is 288nm, and column temperature is 30 ° of C; Get the reference product silibinin appropriate, add moving phase and dissolve and dilute and make the solution that contains silibinin 200 μ g in every 1ml, as the reference product stock solution; Separately get this reference product stock solution and be diluted to the solution of 20 μ g/ml with moving phase, as system suitability solution, get this system suitability solution 20 μ l injection liquid chromatographies, record color atlas; Press out two main chromatographic peaks that A peak and B peak appear being referred to as in peak sequencing successively in this color atlas, the retention time at adjustment A peak is between 6-9min, and the resolution at A peak and B peak should be greater than 1.0 (for example greater than 1.2, for example greater than 1.5, for example greater than 2);
(iii) mensuration of relative retention time (RRt): get the compounds of this invention appropriate, add moving phase and dissolve and make the solution that concentration is 0.5mg/ml, as the trial-product stock solution; Precision measures trial-product stock solution 1ml, puts in the 10ml measuring bottle, is diluted to scale with moving phase, shakes up, and makes to comprise the solution that the compounds of this invention concentration is about 50 μ g/ml, as trial-product test soln I; Another precision measures trial-product stock solution 1ml and reference product stock solution 2.5ml, put in the 10ml measuring bottle, be diluted to scale with moving phase, shake up, make and comprise the solution that the compounds of this invention and reference product silibinin concentration are about respectively 50 μ g/ml, as trial-product test soln II; Precision measures the trial-product test soln II of 20 μ l, and the injection liquid chromatography records color atlas to 2 times of H chromatographic peak retention time; The retention time at four main chromatographic peak E peaks that record in color atlas two main chromatographic peak A peaks being produced by silibinin and B peak and produced by the compounds of this invention, F peak, G peak and H peak, be the relative retention time at E peak divided by the retention time at A peak with the retention time at E peak, be the relative retention time at F peak divided by the retention time at A peak with the retention time at F peak, be the relative retention time at G peak with the retention time at G peak divided by the retention time at A peak, be the relative retention time at H peak with the retention time at H peak divided by the retention time at A peak.
According to the compound of first aspect present invention, its be in following formula I compound by the combination of 12-position and the formed four kinds of isomer of 13-position chiral carbon:
Wherein each X represents hydrogen or metal ion independently of one another;
Described four kinds of isomer account for more than 95% of this compound gross weight, and perhaps the chromatographic purity of this compound is greater than 95%;
this compound is according to high effective liquid chromatography for measuring, press out four main chromatographic peaks that the first chromatographic peak (its in the present invention can referred to as E peak or E) and the second chromatographic peak (its in the present invention can referred to as F peak or F) and tertiary color spectrum peak (its in the present invention can referred to as G peak or G) and the 4th chromatographic peak (its in the present invention can referred to as H peak or H) appear being referred to as in peak sequencing successively in color atlas, described the first chromatographic peak and the second chromatographic peak resolution both are greater than 0.8, described tertiary color spectrum peak and the 4th chromatographic peak resolution both are greater than 1.0, and wherein said the second chromatographic peak peak area is 0.5 ~ 1.5 times (for example 0.7 ~ 1.3 times of described the first chromatographic peak peak area, for example 0.8 ~ 1.2 times), described tertiary color spectrum peak-to-peak area is 4.5 ~ 13.5 times (for example 6.3 ~ 11.7 times of described the first chromatographic peak peak area, for example 7.2 ~ 10.8 times), described the 4th chromatographic peak peak area is 4.5 ~ 13.5 times (for example 6.3 ~ 11.7 times of described the first chromatographic peak peak area, for example 7.2 ~ 10.8 times),
Described high effective liquid chromatography for measuring carries out as follows:
(i) chromatographic condition and system suitability: be the chromatographic column of weighting agent with octadecylsilane chemically bonded silica, take 0.05mol/L sodium dihydrogen phosphate (with phosphoric acid adjust pH to 4.0)-methyl alcohol (50:50) as moving phase, the detection wavelength is 288nm, and column temperature is 30 ° of C; Get the reference product silibinin appropriate, add moving phase and dissolve and dilute and make the solution that contains silibinin 200 μ g in every 1ml, as the reference product stock solution; Separately get this reference product stock solution and be diluted to the solution of 20 μ g/ml with moving phase, as system suitability solution, get this system suitability solution 20 μ l injection liquid chromatographies, record color atlas; Press out two main chromatographic peaks that A peak and B peak appear being referred to as in peak sequencing successively in this color atlas, adjust the retention time at A peak between 6-9min, and the resolution at A peak and B peak should be greater than 1.0;
(ii) chromatographic purity and peak area ratio assay method: get the compounds of this invention appropriate, add moving phase and dissolve and make the solution that concentration is 0.5mg/ml, as need testing solution; Precision measures 1ml, puts in the 100ml measuring bottle, is diluted to scale with moving phase, shakes up, in contrast solution; Adopt the method in (i) chromatographic condition of the present invention and system suitability, get contrast solution 20 μ l injection liquid chromatographies, regulate detection sensitivity, make the peak height of principal constituent H chromatographic peak be about 20% of full range; Precision measures need testing solution and each 20 μ l of contrast solution, and the injection liquid chromatography, record color atlas to 2 times of H chromatographic peak retention time respectively; In the need testing solution color atlas, any chromatographic peak less than 0.05 times of H chromatographic peak area in the contrast solution color atlas is ignored; Record peak area and each impurity peak area at main peak E peak in the need testing solution color atlas, F peak, G peak and H peak, the peak area sum at E peak, F peak, G peak and H peak is divided by whole percentage ratio of peak area sums, be the compounds of this invention chromatographic purity, can calculate respectively to get F peak, G peak and H peak and the peak-to-peak peak area ratio of E with the peak area at F peak, G peak, H peak divided by E peak-to-peak area respectively in addition.
According to the compound of first aspect present invention, its be in following formula I compound by the combination of 12-position and the formed four kinds of isomer of 13-position chiral carbon:
Wherein each X represents hydrogen or metal ion independently of one another;
Described four kinds of isomer account for more than 95% of this compound gross weight, and perhaps the chromatographic purity of this compound is greater than 95%;
This compound is according to high effective liquid chromatography for measuring, presses out the peak sequencing and four main chromatographic peaks that the first chromatographic peak (its in the present invention can referred to as E peak or E) and the second chromatographic peak (its in the present invention can referred to as F peak or F) and tertiary color be composed peak (its in the present invention can referred to as G peak or G) and the 4th chromatographic peak (its in the present invention can referred to as H peak or H) occur successively being referred to as in color atlas;
This compound is according to high effective liquid chromatography for measuring, take silibinin as reference product, and with the A peak of silibinin as the reference peak that calculates relative retention time, the relative retention time (RRt) of the first chromatographic peak of this compound is 1.7 ~ 2.4, the relative retention time (RRt) of the second chromatographic peak of this compound is 1.85 ~ 2.55, the relative retention time (RRt) that the tertiary color of this compound is composed the peak is 2.4 ~ 3.2, and the relative retention time (RRt) of the 4th chromatographic peak of this compound is 2.8 ~ 3.6;
Described high effective liquid chromatography for measuring carries out as follows:
(i) chromatographic condition and system suitability: be the chromatographic column of weighting agent with octadecylsilane chemically bonded silica, take 0.05mol/L sodium dihydrogen phosphate (with phosphoric acid adjust pH to 4.0)-methyl alcohol (50:50) as moving phase, the detection wavelength is 288nm, and column temperature is 30 ° of C; Get the reference product silibinin appropriate, add moving phase and dissolve and dilute and make the solution that contains silibinin 200 μ g in every 1ml, as the reference product stock solution; Separately get this reference product stock solution and be diluted to the solution of 20 μ g/ml with moving phase, as system suitability solution, get this system suitability solution 20 μ l injection liquid chromatographies, record color atlas; Press out two main chromatographic peaks that A peak and B peak appear being referred to as in peak sequencing successively in this color atlas, adjust the retention time at A peak between 6-9min, and the resolution at A peak and B peak should be greater than 1.0;
(iii) mensuration of relative retention time (RRt): get the compounds of this invention appropriate, add moving phase and dissolve and make the solution that concentration is 0.5mg/ml, as the trial-product stock solution; Precision measures trial-product stock solution 1ml, puts in the 10ml measuring bottle, is diluted to scale with moving phase, shakes up, and makes to comprise the solution that the compounds of this invention concentration is about 50 μ g/ml, as trial-product test soln I; Another precision measures trial-product stock solution 1ml and reference product stock solution 2.5ml, put in the 10ml measuring bottle, be diluted to scale with moving phase, shake up, make and comprise the solution that the compounds of this invention and reference product silibinin concentration are about respectively 50 μ g/ml, as trial-product test soln II; Precision measures the trial-product test soln II of 20 μ l, and the injection liquid chromatography records color atlas to 2 times of H chromatographic peak retention time; The retention time at four main chromatographic peak E peaks that record in color atlas two main chromatographic peak A peaks being produced by silibinin and B peak and produced by the compounds of this invention, F peak, G peak and H peak, be the relative retention time at E peak divided by the retention time at A peak with the retention time at E peak, be the relative retention time at F peak divided by the retention time at A peak with the retention time at F peak, be the relative retention time at G peak with the retention time at G peak divided by the retention time at A peak, be the relative retention time at H peak with the retention time at H peak divided by the retention time at A peak.
According to the compound of first aspect present invention, its be in following formula I compound by the combination of 12-position and the formed four kinds of isomer of 13-position chiral carbon:
Wherein each X represents hydrogen or metal ion independently of one another;
Described four kinds of isomer account for more than 95% of this compound gross weight, and perhaps the chromatographic purity of this compound is greater than 95%;
This compound is according to high effective liquid chromatography for measuring, presses out the peak sequencing and four main chromatographic peaks that the first chromatographic peak (its in the present invention can referred to as E peak or E) and the second chromatographic peak (its in the present invention can referred to as F peak or F) and tertiary color be composed peak (its in the present invention can referred to as G peak or G) and the 4th chromatographic peak (its in the present invention can referred to as H peak or H) occur successively being referred to as in color atlas;
Described the first chromatographic peak and the second chromatographic peak resolution both are greater than 0.8, and wherein said the second chromatographic peak peak area is 0.5 ~ 1.5 times of described the first chromatographic peak peak area; Described tertiary color spectrum peak and the 4th chromatographic peak resolution both are greater than 1.0, and wherein said tertiary color spectrum peak-to-peak area is 4.5 ~ 13.5 times of described the first chromatographic peak peak area, and described the 4th chromatographic peak peak area is 4.5 ~ 13.5 times of described the first chromatographic peak peak area;
This compound is according to high effective liquid chromatography for measuring, take silibinin as reference product, and with the A peak of silibinin as the reference peak that calculates relative retention time, the relative retention time (RRt) of the first chromatographic peak of this compound is 1.7 ~ 2.4, the relative retention time (RRt) of the second chromatographic peak of this compound is 1.85 ~ 2.55, the relative retention time (RRt) that the tertiary color of this compound is composed the peak is 2.4 ~ 3.2, and the relative retention time (RRt) of the 4th chromatographic peak of this compound is 2.8 ~ 3.6;
Described high effective liquid chromatography for measuring carries out as follows:
(i) chromatographic condition and system suitability: be the chromatographic column of weighting agent with octadecylsilane chemically bonded silica, take 0.05mol/L sodium dihydrogen phosphate (with phosphoric acid adjust pH to 4.0)-methyl alcohol (50:50) as moving phase, the detection wavelength is 288nm, and column temperature is 30 ° of C; Get the reference product silibinin appropriate, add moving phase and dissolve and dilute and make the solution that contains silibinin 200 μ g in every 1ml, as the reference product stock solution; Separately get this reference product stock solution and be diluted to the solution of 20 μ g/ml with moving phase, as system suitability solution, get this system suitability solution 20 μ l injection liquid chromatographies, record color atlas; Press out two main chromatographic peaks that A peak and B peak appear being referred to as in peak sequencing successively in this color atlas, adjust the retention time at A peak between 6-9min, and the resolution at A peak and B peak should be greater than 1.0;
(ii) chromatographic purity and peak area ratio assay method: get the compounds of this invention appropriate, add moving phase and dissolve and make the solution that concentration is 0.5mg/ml, as need testing solution; Precision measures 1ml, puts in the 100ml measuring bottle, is diluted to scale with moving phase, shakes up, in contrast solution; Adopt the method in (i) chromatographic condition of the present invention and system suitability, get contrast solution 20 μ l injection liquid chromatographies, regulate detection sensitivity, make the peak height of principal constituent H chromatographic peak be about 20% of full range; Precision measures need testing solution and each 20 μ l of contrast solution, and the injection liquid chromatography, record color atlas to 2 times of H chromatographic peak retention time respectively; In the need testing solution color atlas, any chromatographic peak less than 0.05 times of H chromatographic peak area in the contrast solution color atlas is ignored; Record peak area and each impurity peak area at main peak E peak in the need testing solution color atlas, F peak, G peak and H peak, the peak area sum at E peak, F peak, G peak and H peak is divided by whole percentage ratio of peak area sums, be the compounds of this invention chromatographic purity, can calculate respectively to get F peak, G peak and H peak and the peak-to-peak peak area ratio of E with the peak area at F peak, G peak, H peak divided by E peak-to-peak area respectively in addition;
(iii) mensuration of relative retention time (RRt): get the compounds of this invention appropriate, add moving phase and dissolve and make the solution that concentration is 0.5mg/ml, as the trial-product stock solution; Precision measures trial-product stock solution 1ml, puts in the 10ml measuring bottle, is diluted to scale with moving phase, shakes up, and makes to comprise the solution that the compounds of this invention concentration is about 50 μ g/ml, as trial-product test soln I; Another precision measures trial-product stock solution 1ml and reference product stock solution 2.5ml, put in the 10ml measuring bottle, be diluted to scale with moving phase, shake up, make and comprise the solution that the compounds of this invention and reference product silibinin concentration are about respectively 50 μ g/ml, as trial-product test soln II; Precision measures the trial-product test soln II of 20 μ l, and the injection liquid chromatography records color atlas to 2 times of H chromatographic peak retention time; The retention time at four main chromatographic peak E peaks that record in color atlas two main chromatographic peak A peaks being produced by silibinin and B peak and produced by the compounds of this invention, F peak, G peak and H peak, be the relative retention time at E peak divided by the retention time at A peak with the retention time at E peak, be the relative retention time at F peak divided by the retention time at A peak with the retention time at F peak, be the relative retention time at G peak with the retention time at G peak divided by the retention time at A peak, be the relative retention time at H peak with the retention time at H peak divided by the retention time at A peak.
Second aspect present invention provides a kind of pharmaceutical composition, wherein comprises the described compound of the arbitrary embodiment of first aspect present invention and optional pharmaceutical excipient.In one embodiment, the described compound as activeconstituents comprises in formula I compound of the present invention by 12-position and the formed four kinds of isomer of 13-position chiral carbon.In one embodiment, in this pharmaceutical composition, four kinds of isomer account for the 1-99% of this pharmaceutical composition gross weight.
According to the pharmaceutical composition of second aspect present invention, wherein comprise as in the following formula I compound of activeconstituents by 12-position and the 13-formed four kinds of isomer of position chiral carbon and optional pharmaceutical excipient:
Wherein each X represents hydrogen or metal ion independently of one another;
This pharmaceutical composition is according to high effective liquid chromatography for measuring, disregard the auxiliary material chromatographic peak, press out four main chromatographic peaks that the first chromatographic peak (its in the present invention can referred to as E peak or E) and the second chromatographic peak (its in the present invention can referred to as F peak or F) and tertiary color spectrum peak (its in the present invention can referred to as G peak or G) and the 4th chromatographic peak (its in the present invention can referred to as H peak or H) appear being referred to as in peak sequencing successively in color atlas
Described the first chromatographic peak and the second chromatographic peak resolution both are greater than 0.8, and wherein said the second chromatographic peak peak area is 0.5 ~ 1.5 times of described the first chromatographic peak peak area; Described tertiary color spectrum peak and the 4th chromatographic peak resolution both are greater than 1.0, and wherein said tertiary color spectrum peak-to-peak area is 4.5 ~ 13.5 times of described the first chromatographic peak peak area, and described the 4th chromatographic peak peak area is 4.5 ~ 13.5 times of described the first chromatographic peak peak area;
Described high effective liquid chromatography for measuring carries out as follows:
(i) chromatographic condition and system suitability: be the chromatographic column of weighting agent with octadecylsilane chemically bonded silica, take 0.05mol/L sodium dihydrogen phosphate (with phosphoric acid adjust pH to 4.0)-methyl alcohol (50:50) as moving phase, the detection wavelength is 288nm, and column temperature is 30 ° of C; Get the reference product silibinin appropriate, add moving phase and dissolve and dilute and make the solution that contains silibinin 200 μ g in every 1ml, as the reference product stock solution; Separately get this reference product stock solution and be diluted to the solution of 20 μ g/ml with moving phase, as system suitability solution, get this system suitability solution 20 μ l injection liquid chromatographies, record color atlas; Press out two main chromatographic peaks that A peak and B peak appear being referred to as in peak sequencing successively in this color atlas, adjust the retention time at A peak between 6-9min, and the resolution at A peak and B peak should be greater than 1.0;
(ii) chromatographic purity and peak area ratio assay method: get pharmaceutical composition of the present invention appropriate, add moving phase and dissolve and make that to contain formula I compound concentration be the solution of 0.5mg/ml, as need testing solution; Precision measures 1ml, puts in the 100ml measuring bottle, is diluted to scale with moving phase, shakes up, in contrast solution; Adopt the method in (i) chromatographic condition of the present invention and system suitability, get contrast solution 20 μ l injection liquid chromatographies, regulate detection sensitivity, make the peak height of principal constituent H chromatographic peak be about 20% of full range; Precision measures need testing solution and each 20 μ l of contrast solution, and the injection liquid chromatography, record color atlas to 2 times of H chromatographic peak retention time respectively; In the need testing solution color atlas, any chromatographic peak less than 0.05 times of H chromatographic peak area in the contrast solution color atlas is ignored, and also ignores in the auxiliary material peak; Record peak area and each impurity peak area at main peak E peak in the need testing solution color atlas, F peak, G peak and H peak, the peak area sum at E peak, F peak, G peak and H peak is divided by whole percentage ratio of peak area sums, be pharmaceutical composition chromatographic purity of the present invention, can calculate respectively to get F peak, G peak and H peak and the peak-to-peak peak area ratio of E with the peak area at F peak, G peak, H peak divided by E peak-to-peak area respectively in addition.
According to the pharmaceutical composition of second aspect present invention, wherein comprise as in the following formula I compound of activeconstituents by 12-position and the 13-formed four kinds of isomer of position chiral carbon and optional pharmaceutical excipient:
Wherein each X represents hydrogen or metal ion independently of one another;
This pharmaceutical composition is according to high effective liquid chromatography for measuring, disregard the auxiliary material chromatographic peak, press out four main chromatographic peaks that the first chromatographic peak (its in the present invention can referred to as E peak or E) and the second chromatographic peak (its in the present invention can referred to as F peak or F) and tertiary color spectrum peak (its in the present invention can referred to as G peak or G) and the 4th chromatographic peak (its in the present invention can referred to as H peak or H) appear being referred to as in peak sequencing successively in color atlas;
This pharmaceutical composition is according to high effective liquid chromatography for measuring, take silibinin as reference product, and with the A peak of silibinin as the reference peak that calculates relative retention time, the relative retention time (RRt) of the first chromatographic peak of this pharmaceutical composition is 1.7 ~ 2.4, the relative retention time (RRt) of the second chromatographic peak of this pharmaceutical composition is 1.85 ~ 2.55, the relative retention time (RRt) that the tertiary color of this pharmaceutical composition is composed the peak is 2.4 ~ 3.2, and the relative retention time (RRt) of the 4th chromatographic peak of this pharmaceutical composition is 2.8 ~ 3.6;
Described high effective liquid chromatography for measuring carries out as follows:
(i) chromatographic condition and system suitability: be the chromatographic column of weighting agent with octadecylsilane chemically bonded silica, take 0.05mol/L sodium dihydrogen phosphate (with phosphoric acid adjust pH to 4.0)-methyl alcohol (50:50) as moving phase, the detection wavelength is 288nm, and column temperature is 30 ° of C; Get the reference product silibinin appropriate, add moving phase and dissolve and dilute and make the solution that contains silibinin 200 μ g in every 1ml, as the reference product stock solution; Separately get this reference product stock solution and be diluted to the solution of 20 μ g/ml with moving phase, as system suitability solution, get this system suitability solution 20 μ l injection liquid chromatographies, record color atlas; Press out two main chromatographic peaks that A peak and B peak appear being referred to as in peak sequencing successively in this color atlas, adjust the retention time at A peak between 6-9min, and the resolution at A peak and B peak should be greater than 1.0;
(iii) mensuration of relative retention time (RRt): get pharmaceutical composition of the present invention appropriate, add moving phase and dissolve and make that to contain formula I compound concentration be the solution of 0.5mg/ml, as the trial-product stock solution; Precision measures trial-product stock solution 1ml, puts in the 10ml measuring bottle, is diluted to scale with moving phase, shakes up, and makes to comprise to contain the solution that formula I compound concentration is about 50 μ g/ml, as trial-product test soln I; Another precision measures trial-product stock solution 1ml and reference product stock solution 2.5ml, put in the 10ml measuring bottle, be diluted to scale with moving phase, shake up, make to comprise and contain the solution that formula I compound and reference product silibinin concentration are about respectively 50 μ g/ml, as trial-product test soln II; Precision measures the trial-product test soln II of 20 μ l, and the injection liquid chromatography records color atlas to 2 times of H chromatographic peak retention time; Record in color atlas two main chromatographic peak A peaks being produced by silibinin and B peak and by the retention time at four main chromatographic peak E peaks of drug regimen deposits yields of the present invention, F peak, G peak and H peak, be the relative retention time at E peak divided by the retention time at A peak with the retention time at E peak, be the relative retention time at F peak divided by the retention time at A peak with the retention time at F peak, be the relative retention time at G peak with the retention time at G peak divided by the retention time at A peak, be the relative retention time at H peak with the retention time at H peak divided by the retention time at A peak.
According to the pharmaceutical composition of second aspect present invention, wherein comprise as in the following formula I compound of activeconstituents by 12-position and the 13-formed four kinds of isomer of position chiral carbon and optional pharmaceutical excipient:
Wherein each X represents hydrogen or metal ion independently of one another;
This pharmaceutical composition is according to high effective liquid chromatography for measuring, disregard the auxiliary material chromatographic peak, press out four main chromatographic peaks that the first chromatographic peak (its in the present invention can referred to as E peak or E) and the second chromatographic peak (its in the present invention can referred to as F peak or F) and tertiary color spectrum peak (its in the present invention can referred to as G peak or G) and the 4th chromatographic peak (its in the present invention can referred to as H peak or H) appear being referred to as in peak sequencing successively in color atlas;
Described the first chromatographic peak and the second chromatographic peak resolution both are greater than 0.8, and wherein said the second chromatographic peak peak area is 0.5 ~ 1.5 times of described the first chromatographic peak peak area; Described tertiary color spectrum peak and the 4th chromatographic peak resolution both are greater than 1.0, and wherein said tertiary color spectrum peak-to-peak area is 4.5 ~ 13.5 times of described the first chromatographic peak peak area, and described the 4th chromatographic peak peak area is 4.5 ~ 13.5 times of described the first chromatographic peak peak area;
This pharmaceutical composition is according to high effective liquid chromatography for measuring, take silibinin as reference product, and with the A peak of silibinin as the reference peak that calculates relative retention time, the relative retention time (RRt) of the first chromatographic peak of this pharmaceutical composition is 1.7 ~ 2.4, the relative retention time (RRt) of the second chromatographic peak of this pharmaceutical composition is 1.85 ~ 2.55, the relative retention time (RRt) that the tertiary color of this pharmaceutical composition is composed the peak is 2.4 ~ 3.2, and the relative retention time (RRt) of the 4th chromatographic peak of this pharmaceutical composition is 2.8 ~ 3.6;
Described high effective liquid chromatography for measuring carries out as follows:
(i) chromatographic condition and system suitability: be the chromatographic column of weighting agent with octadecylsilane chemically bonded silica, take 0.05mol/L sodium dihydrogen phosphate (with phosphoric acid adjust pH to 4.0)-methyl alcohol (50:50) as moving phase, the detection wavelength is 288nm, and column temperature is 30 ° of C; Get the reference product silibinin appropriate, add moving phase and dissolve and dilute and make the solution that contains silibinin 200 μ g in every 1ml, as the reference product stock solution; Separately get this reference product stock solution and be diluted to the solution of 20 μ g/ml with moving phase, as system suitability solution, get this system suitability solution 20 μ l injection liquid chromatographies, record color atlas; Press out two main chromatographic peaks that A peak and B peak appear being referred to as in peak sequencing successively in this color atlas, adjust the retention time at A peak between 6-9min, and the resolution at A peak and B peak should be greater than 1.0;
(ii) chromatographic purity and peak area ratio assay method: get pharmaceutical composition of the present invention appropriate, add moving phase and dissolve and make that to contain formula I compound concentration be the solution of 0.5mg/ml, as need testing solution; Precision measures 1ml, puts in the 100ml measuring bottle, is diluted to scale with moving phase, shakes up, in contrast solution; Adopt the method in (i) chromatographic condition of the present invention and system suitability, get contrast solution 20 μ l injection liquid chromatographies, regulate detection sensitivity, make the peak height of principal constituent H chromatographic peak be about 20% of full range; Precision measures need testing solution and each 20 μ l of contrast solution, and the injection liquid chromatography, record color atlas to 2 times of H chromatographic peak retention time respectively; In the need testing solution color atlas, any chromatographic peak less than 0.05 times of H chromatographic peak area in the contrast solution color atlas is ignored, and also ignores in the auxiliary material peak; Record peak area and each impurity peak area at main peak E peak in the need testing solution color atlas, F peak, G peak and H peak, the peak area sum at E peak, F peak, G peak and H peak is divided by whole percentage ratio of peak area sums, be pharmaceutical composition chromatographic purity of the present invention, can calculate respectively to get F peak, G peak and H peak and the peak-to-peak peak area ratio of E with the peak area at F peak, G peak, H peak divided by E peak-to-peak area respectively in addition;
(iii) mensuration of relative retention time (RRt): get pharmaceutical composition of the present invention appropriate, add moving phase and dissolve and make that to contain formula I compound concentration be the solution of 0.5mg/ml, as the trial-product stock solution; Precision measures trial-product stock solution 1ml, puts in the 10ml measuring bottle, is diluted to scale with moving phase, shakes up, and makes to comprise to contain the solution that formula I compound concentration is about 50 μ g/ml, as trial-product test soln I; Another precision measures trial-product stock solution 1ml and reference product stock solution 2.5ml, put in the 10ml measuring bottle, be diluted to scale with moving phase, shake up, make to comprise and contain the solution that formula I compound and reference product silibinin concentration are about respectively 50 μ g/ml, as trial-product test soln II; Precision measures the trial-product test soln II of 20 μ l, and the injection liquid chromatography records color atlas to 2 times of H chromatographic peak retention time; Record in color atlas two main chromatographic peak A peaks being produced by silibinin and B peak and by the retention time at four main chromatographic peak E peaks of drug regimen deposits yields of the present invention, F peak, G peak and H peak, be the relative retention time at E peak divided by the retention time at A peak with the retention time at E peak, be the relative retention time at F peak divided by the retention time at A peak with the retention time at F peak, be the relative retention time at G peak with the retention time at G peak divided by the retention time at A peak, be the relative retention time at H peak with the retention time at H peak divided by the retention time at A peak.
pharmaceutical composition according to second aspect present invention, it is according to high effective liquid chromatography for measuring, disregard the auxiliary material chromatographic peak, press out four main chromatographic peaks that the first chromatographic peak (its in the present invention can referred to as E peak or E) and the second chromatographic peak (its in the present invention can referred to as F peak or F) and tertiary color spectrum peak (its in the present invention can referred to as G peak or G) and the 4th chromatographic peak (its in the present invention can referred to as H peak or H) appear being referred to as in peak sequencing successively in color atlas, described the first chromatographic peak, the second chromatographic peak, the peak area sum of tertiary color spectrum peak and the 4th chromatographic peak accounts for more than 95% of total peak area.
Third aspect present invention provides the method for preparing the described compound of the arbitrary embodiment of first aspect present invention, and it comprises the following steps:
(a) esterif iotacation step: make silibinin shown in following formula:
Dissolve in suitable organic solvent, add succinyl oxide, in 5 ~ 50 hours (for example 10 ~ 40 hours, for example 15 ~ 30 hours) of the lower reaction of 30 ~ 80 ° of C temperature (for example 35 ~ 50 ° of C);
(b) hydrolysing step: add appropriate 50 ~ 90% ethanol (for example 65 ~ 85% ethanol) in step (a) gained reaction solution, continue at the lower stirring reaction of 30 ~ 80 ° of C temperature (for example 35 ~ 50 ° of C) complete to hydrolysis; Be cooled to room temperature, add that 2 ~ 8mol/L hydrochloric acid is appropriate and ethyl acetate is appropriate, after surveying this mixture and be acidity with the pH test paper, add water, stir 5 ~ 60min, after standing demix, discard lower aqueous layer, organic layer washes with water, is neutral until water layer shows, standing demix, the organic layer decolorizing with activated carbon filters, and collects filtrate, desolventizing obtains silibinin 3-position hydroxyl and 12-position methylol and forms silybin bis-bias succinate shown in the following formula of partial ester with succsinic acid respectively:
(c) separating step: use the preparative liquid chromatography method to separate, be that (for example packing material size is 10 μ m to chromatograph packing material with octadecylsilane chemically bonded silica, can be for example that brand is the C18 chromatograph packing material of Daiso SP-100-10-ODS-P) in the dynamic axial compression column preparative liquid chromatography system of packing into (can be for example the DAC-HB80 dynamic axial compression column system of Hanbon Sci. ﹠ Tech. Co., Ltd.), take 0.05mol/L sodium dihydrogen phosphate (with phosphoric acid adjust pH to 4.0)-methyl alcohol (50:50) as moving phase, the detection wavelength is 288nm, step (b) products therefrom is dissolved with moving phase, use the sampling pump sample introduction, wash-out also records the extremely whole complete wash-outs of chromatographic peak of color atlas out, take the retention time of last chromatographic peak as benchmark, the intercepting relative retention time is at two chromatographic peaks out of wash-out between 0.4 ~ 0.7 and the elutriant that comprises altogether four chromatographic peaks of relative retention time wash-out two chromatographic peaks out between 0.7 ~ 1.0,
(d) extraction step: measure step (c) the gained elutriant of 1 volume to the separatory pan, then add the pure water of 0.5 ~ 2 volume, after mixing, then add the ethyl acetate of 0.5 ~ 2 volume, shaking out, standing demix discards lower floor's waste liquid; The upper strata ethyl acetate layer adds 0.5 ~ 2 volume pure water, shaking out, standing demix, discard lower aqueous layer, so repeat 2 times or more than, ethyl acetate layer is in 30 ~ 50 ° of C desolventizings (for example 35-50 ° of C, for example approximately 40 ° of C rotary evaporations desolventize), dry (for example in 50 ~ 70 ° of C vacuum-dryings) obtain silybin bis-bias succinate; With optional
(e) salify step: step (d) gained silybin bis-bias succinate is dissolved in organic solvent (for example methyl alcohol, dehydrated alcohol), the solution (for example being dissolved in the solution in organic solvent (for example methyl alcohol, dehydrated alcohol)) that adds again alkali metal hydroxide or alkaline earth metal hydroxides, stirring makes reaction, separate out white solid, filter, drying obtains an alkali metal salt or the alkaline earth salt of silybin bis-bias succinate.
Fourth aspect present invention provides the described compound of the arbitrary embodiment of first aspect present invention for the preparation of the purposes in the medicine for the treatment of, improvement or prevention of liver disease.
According to the purposes of fourth aspect present invention, wherein said hepatic diseases is selected from: because of the Acute Hepatic that Amanita phalloides causes poisoning, acute, chronic hepatitis, first cirrhosis, toxic hepatitis, dysfunction of liver due to fatty liver, dysfunction of liver due to alcoholic liver.
Fifth aspect present invention relates to a kind of method for the treatment of in the Mammals of needs (comprising the people) is arranged, improvement or prevention of liver disease, and the method comprises the described compound of the arbitrary embodiment of first aspect present invention to the administration treatment significant quantity that needs are arranged.In one embodiment, described hepatic diseases is selected from: because of the Acute Hepatic that Amanita phalloides causes poisoning, acute, chronic hepatitis, first cirrhosis, toxic hepatitis, dysfunction of liver due to fatty liver, dysfunction of liver due to alcoholic liver.
Sixth aspect present invention relates to and being used for the treatment of, improves or prevent the pharmaceutical composition of Mammals (comprising the people) hepatic diseases, this pharmaceutical composition comprises the described compound of the arbitrary embodiment of first aspect present invention, and optional one or more pharmaceutically acceptable carriers or vehicle.
Seventh aspect present invention relates to and being used for the treatment of, improves or prevent the described compound of the arbitrary embodiment of first aspect present invention of Mammals (comprising the people) hepatic diseases.
Arbitrary embodiment of either side of the present invention can make up with other embodiment, as long as they contradiction can not occur.In addition, in arbitrary embodiment of either side of the present invention, arbitrary technical characterictic goes for this technical characterictic in other embodiment, as long as they contradiction can not occur.
Arbitrary embodiment of applicable equally other the arbitrary embodiment of arbitrary technical characterictic that arbitrary embodiment of either side of the present invention or this either side has or other either side, as long as they can be not conflicting, certainly at where applicable each other, necessary words can be done suitably to modify to individual features.The below is further described with characteristics to various aspects of the present invention.
All documents that the present invention quotes from, their full content is incorporated this paper by reference into, and if when the expressed implication of these documents and the present invention are inconsistent, be as the criterion with statement of the present invention.In addition, various terms and phrase that the present invention uses have the general sense of well known to a person skilled in the art, nonetheless, the present invention still wishes at this, these terms and phrase to be described in more detail and to explain, the term of mentioning and phrase are as the criterion with the implication that the present invention was explained if any inconsistent with known implication.
As everyone knows, silibinin (C25H22O10, M.W.482.60) has following structural formula:
The annular atoms numbering of five rings in its structure is as follows:
The silibinin that obtains from the feverfew Silymarin, people can determine that wherein 2-position and 3-position are the R configuration, but the configuration for 12-position and two places, 13-position but it be unclear that, even the possible configuration of bibliographical information has been arranged 12-position and 13-position is only also to infer.In the present invention, if not otherwise indicated, when mentioning the 12-position of silibinin or silybin bis-bias succinate or its salt and 13-position, respectively as the 12-position that indicates of above structure and 13-two of positions ring carbon atom.
the salt of silybin bis-bias succinate is sodium salt for example, also can be described as SDH or SDH, to be that 3, the chromene ring of silibinin is upper replace with succsinic acid for it, and replace with succsinic acid on 2 methyl of benzodioxane, the disodium salt that forms therefrom, its chemical name is: mono succinate [[6-[3-(3-carboxyl-1-oxygen propoxy-)-3, 4-dihydro-5, 7-dihydroxyl-4-oxygen-2H-1-chromene-2-yl]-2, 3-dihydro-3-(4-hydroxy 3-methoxybenzene base)-1, 4-benzodioxane-2-yl] methyl] the ester disodium, perhaps Butanedioic acid, mono ((6-(3-(3-carboxy-1-oxopropoxy)-3, 4-dihydro-5, 7-dihydroxy-4-oxo-2H-1-benzopyran-2-yl)-2, 3-dihydro-3-(4-hydroxy-3-methoxyphenyl)-1, 4-benzodioxin-2-yl) methyl) ester, disodium salt.Its molecular formula is: C
33H
28O
16Na
2, molecular weight is: 726.48, and namely following formula is 32-position carboxyl and the formed sodium salt of 36-position carboxyl on silybin bis-bias succinate.
That pharmaceutical composition of the present invention can be used for is acute, the chronic hepatic injury treatment, also can be used for the recovery of the dysfunction of liver that fatty liver and alcoholic liver cause.The preparation that pharmaceutical composition of the present invention particularly is drug administration by injection in use, can instil with 0.9% sodium chloride injection or 5% glucose injection dilution posterior vein, for example shot 5mg/kg, for example can annotate in 2 hours, and for example injection in a day is 1,2,3 or 4 time.In addition, pharmaceutical composition of the present invention can be used for liver that Amanita fuliginea causes when poisoning, in the case, should bring into use as early as possible pharmaceutical composition of the present invention, until till toxicity symptom disappears.
Activeconstituents formula I compound in pharmaceutical composition of the present invention is silybin bis-bias succinate or its salt (can be abbreviated as SDH in this article), it has anti-oxidant activity, it has restraining effect to liver microsomes and the peroxidation of plastosome phosphatide that free radical mediates, and has the film stabilizing effect.Rat intravenous injection SDH can suppress the oxygen luxus consumption of phenylhydrazine mediation and the peroxidation of phosphatide, weakens the increase trend of paddy Guang liver peptide (GSH), and SDH also can be reduced to normal level with this effect.SDH can reduce the impact of ethanol metabolic process in vivo, especially MEOS, and the phospholipid metabolism that also can correct the liver that is caused by ethanol is disorderly.It is active that formula I compound also has anti-liver toxicity, and rats by intraperitoneal injection SDH can strengthen the activity of total phosphide, free cholesterol, triglyceride level, total phospholipids and phosphatidyl thanomin and the triglyceride in serum of liver.SDH has the Synthesis that reduces the postmitochondrial lipid acid of rat.In addition, formula I compound also has the toxinicide effect, SDH to toxicant example hydrochloric acid D-galactosamine, metal praseodymium with and compound (Pr (NO
3)
3), No. 3, phenylhydrazine, frog virus, isonitrile acid α naphthalene ester etc. also produce effect to the infringement of liver.Moreover formula I compound also antagonistic drug source liver injury have provide protection, the hepatic injury that the medicines such as Paracetamol and phenylethyl barbituric acid are caused has provide protection.
In the present invention, when mentioning " formula I compound ", refer to any possible whole isomer of silybin bis-bias succinate shown in formula I or its salt, as long as these isomer meet the individual features of high performance liquid chromatography of the present invention; Particularly 2-position and 3-position are the R configuration, and 12-position and 13-position are the isomer of arbitrary configuration.
In the present invention, when mentioning " compound " or " the compounds of this invention ", any possible whole isomer mixture together of silybin bis-bias succinate or its salt shown in finger formula I is as long as these isomer meet the individual features of high performance liquid chromatography of the present invention; Particularly 2-position and 3-position are the R configuration, and 12-position and 13-position are the isomer of arbitrary configuration.Thus, have four kinds of isomer in " the compounds of this invention ", these isomer are the R configuration in the 2-position of silybin bis-bias succinate shown in formula I or its salt and 3-position, and are arbitrary configuration in 12-position and 13-position.In addition, " compound " mentioned or " the compounds of this invention " only contain four kinds of isomer of this paper definition basically, and basically do not comprise other material, but the impurity of small quantity is allowed existence, for example allow exist less than 5%, the isomer less than 4%, less than 3%, less than 2%, less than 1%.
In many embodiments of the present invention, the compounds of this invention is comprised of four kinds of isomer of formula I compound, and more particularly, these four kinds of isomer are the R configuration in 2-position and 3-position.It is extremely low and can be understood as in the situation of impurity that another kind of isomer, particularly these content of isomer with formula I structure are not exclusively repelled in above-mentioned " the compounds of this invention is comprised of four kinds of isomer of formula I compound " or similar closed statement.In addition, although the present invention it be unclear that four kinds of isomer at the concrete configuration of 12-position and 13-position, yet the present invention can determine the compounds of this invention clearly by chromatographic behavior.Especially, under the HPLC condition of the present invention's regulation, for example this can make two chromatographic peak resolution of reference product silibinin reach more than 0.8 and the peak retention time that first the elutes condition at about 6-9min under, four isomer in the compounds of this invention have resolution greater than 0.8 and each peak have basic fixing relative retention time, although the inventor still can not determine the concrete configuration of four isomer in the compounds of this invention thus, however can be by the concrete composition of the unique definite the compounds of this invention of this mode.
In the present invention, symbol % according to its linguistic context of using, can have those skilled in the art and hold intelligible implication.For example when mentioning solid content, the percentage ratio of this symbolic representation weight/volume (w/v, for example g/100ml); For example during " water-content " in mentioning the lyophilize powder injection, for example water-content is below 8% again, and this moment, this symbol % represented the percentage ratio (w/w, g/100g) of w/w.Generally speaking, when solid was dispersed in liquid, % represented weight/volume percentage ratio; Solid be dispersed in solid or liquid dispersion in solid when (for example water content of powder pin), % represents w/w percentage ratio.In other cases, unless otherwise noted, symbol % represents w/w percentage ratio.
In the present invention, the silibinin that uses product/reference material/reference product in contrast or raw material all can be buied from market, perhaps adopts the disclosed method preparation of prior art.
In the present invention, when carrying out the calculating of chromatographic peak, all do not consider the chromatographic peak that auxiliary material forms, do not consider the chromatographic peak that test soln solvent and/or moving phase form yet, when concrete calculating, may deduct these solvents, moving phase or the corresponding chromatographic peak of auxiliary material solution when calculating each sample by inject solvent, moving phase or auxiliary material solution in chromatographic instrument, this practice is the particularly known basic skills of pharmaceutical analysis those skilled in the art of those skilled in the art.
In preparing the method for material of the present invention, the various starting material that react used are that those skilled in the art can prepare according to existing knowledge, or can make by the known method of document, or can buy by business.In above reaction scheme, intermediate used, starting material, reagent, reaction conditions etc. all can knowledge existing according to those skilled in the art can be made appropriate change.
The compounds of this invention can be used in combination with other activeconstituents, as long as it does not produce other detrimental actions, for example anaphylaxis.
The compounds of this invention can be used as unique active medicine and uses, perhaps can with one or more other physiologically actives on have the Drug combination of collaborative and/or synergism with material of the present invention.Combination therapy can realize by each being treated component while, order or separating administration.
Term used herein " composition " means to comprise the product of respectively specifying composition that comprises specified amount, and directly or indirectly from any product of the combination results of respectively specifying composition of specified amount.In the present invention, term " composition " can with " pharmaceutical composition " Alternate.
The active matter quality of gained can change the actual dose level of each activeconstituents in pharmaceutical composition of the present invention, so that can effectively obtain required therapeutic response for concrete patient, compound and administering mode.The dosage level fibrous root is selected according to activity, route of administration, the severity of the patient's condition for the treatment of and the patient's to be treated patient's condition and the medical history of concrete active substance.But the way of this area is, the dosage of active substance is from lower than increasing gradually dosage, until obtain required effect for obtaining level that required result for the treatment of requires.
When being used for above-mentioned treat and/or prevent or when other treatment and/or prevention, a kind of the compounds of this invention that treats and/or prevents significant quantity can be used with pure form, perhaps uses with the acceptable ester of pharmacy or prodrug forms (in the situation that having these forms).Perhaps, described compound can be accepted the pharmaceutical composition administration of vehicle to contain this purpose compound and one or more medicines.The compounds of this invention that word " treats and/or prevents significant quantity " refers to be applicable to the reasonable effect of any therapeutic treatment and/or prevention/risk than the compound of the q.s for the treatment of obstacle.But the total daily dosage portion that it should be understood that the compounds of this invention and pharmaceutical composition must be examined the doctor by the master and maked decision in the medical judgment scope reliably.For any concrete patient, the concrete horizontal fibrous root for the treatment of effective dose is decided according to many factors, and described factor comprises the severity of the obstacle for the treatment of and this obstacle; The activity of the particular compound that adopts; The concrete pharmaceutical composition that adopts; Patient's age, body weight, general health situation, sex and diet; The administration time of the concrete pharmaceutical composition that adopts, route of administration and excretion rate; The treatment time length; With the pharmaceutical composition use of adopting or the other medicines that use simultaneously; And the known similar factor of medical field.For example, the way of this area is, the dosage of pharmaceutical composition is from lower than increasing gradually dosage, until obtain required effect for obtaining level that required result for the treatment of requires.In general, particularly people's dosage can be between 0.001～1000mg/kg body weight/day, for example between 0.01～100mg/kg body weight/day, for example between 0.01～10mg/kg body weight/day for Mammals for the compounds of this invention.
The pharmaceutical carrier that uses those skilled in the art to be familiar with can be prepared into the pharmaceutical composition of the compounds of this invention that contains effective dosage.Therefore the present invention also provides the pharmaceutical composition that comprises with one or more nontoxic drug acceptable carriers the compounds of this invention formulated together.That described pharmaceutical composition can be mixed with especially specially is for oral administration with solid or liquid form, for the parenteral injection or for rectal administration.
Described pharmaceutical composition can be mixed with many formulations, is convenient to administration, for example, and oral preparations (as tablet, capsule, solution or suspension); Injectable preparation (as injectable solution or suspension, or injectable dried powder, add injection water to use immediately before injection).in described pharmaceutical composition, carrier comprises: the tackiness agent that oral preparations uses is (as starch, corn normally, wheat or rice starch, gelatin, methylcellulose gum, Xylo-Mucine and/or polyvinylpyrrolidone), thinner, lubricant is (as silicon-dioxide, talcum, stearic acid or its salt, normally Magnesium Stearate or calcium stearate, and/or polyoxyethylene glycol), and if necessary, also contain disintegrating agent, as starch, agar, Lalgine or its salt, sodiun alginate normally, and/or effervescent mixture, solubility promoter, stablizer, suspension agent, tinting material, correctives etc., the sanitas that injectable preparation uses, solubilizing agent, stablizer etc., the matrix that topical formulations is used, thinner, lubricant etc.Pharmaceutical preparation can oral administration or parenteral mode (for example intravenously, subcutaneous, intraperitoneal or part) administration, if some drugs is unsettled under the stomach condition, it can be mixed with enteric coated tablets.
More particularly, pharmaceutical composition of the present invention can by in oral, rectum, parenteral, pond, intravaginal, intraperitoneal, part (as by powder, ointment or drops), a mouthful cheek give the mankind and other Mammalss, perhaps give as oral spray or nasal mist.Term used herein " parenteral " refers to comprise intravenously, intramuscular, intraperitoneal, breastbone is interior, subcutaneous and the administering mode of intra-articular injection and transfusion.
The pharmaceutical composition that is suitable for the parenteral injection can comprise physiologically acceptable aseptic moisture or non-aqueous solution agent, dispersion agent, suspensoid or emulsion, and for the aseptic powder that reconstitutes sterile injectable solution agent or dispersion agent.Suitable moisture or nonaqueous carrier, thinner, solvent or vectorial example comprise water, ethanol, polyvalent alcohol (propylene glycol, polyoxyethylene glycol, glycerine etc.), vegetables oil (as sweet oil), injectable organic ester such as ethyl oleate and their suitable mixture.
These pharmaceutical compositions also can contain auxiliary material, as sanitas, wetting agent, emulsifying agent and dispersion agent.By various antibacterial agents and anti-mycotic agent, such as parabens, trichloro-butyl alcohol, phenol, Sorbic Acid etc. can guarantee to prevent the effect of microorganism.Also expectation comprises isotonic agent, such as carbohydrate, sodium-chlor etc.By using the material that can postpone absorption, for example aluminum monostearate and gelatin, can reach the prolongation absorption of injectable drug form.
Also can contain suspension agent except the active ingredient beyond the region of objective existence in suspensoid, such as ethoxylation i-octadecanol, polyoxyethylene sorbitol and polyoxyethylene sorbitan esters, Microcrystalline Cellulose, the mixture etc. of aluminium hydroxide, wilkinite, agar and tragacanth gum or these materials partially.
In some cases, be the effect of prolong drug, expect to slow down absorption subcutaneous or the intramuscularly medicine.This can be by realizing with the crystal of poorly water-soluble or the liquid suspension of amorphous substance.Like this, the absorption rate of medicine depends on its dissolution rate, and dissolution rate can be depending on crystallographic dimension and crystal formation.Perhaps, the delay of the medicament forms of parenteral admin absorb by with this medicine dissolution in or be suspended in oily vehicle and realize.
The injectable depot formulations form can prepare by the microcapsule matrix that forms medicine in biodegradable polymer such as polylactide-PGA.Can according to the character of medicine with ratio with the concrete polymkeric substance that adopts of polymkeric substance, drug releasing rate be controlled.The example of other biological degradable polymer comprises poe class and polyanhydrides.Injectable depot formulations also can by pharmaceutical pack is embedded in can be compatible with bodily tissue liposome or micro emulsion in prepare.
Injectable formulation can be for example by filtering or sterilize by the disinfectant that mixes the aseptic solid composite form with bacterial filter, and described solids composition can be dissolved or dispersed in sterilized water or other sterile injectable medium before use.
The compounds of this invention or its pharmaceutical composition can be with oral methods or parenteral administration modes.Oral administration can be tablet, capsule, Drug coating, and the enteron aisle external application preparation has injection and suppository etc.These preparations prepare according to method appreciated by those skilled in the art.The auxiliary material of conventional use in order to make tablet, capsule, Drug coating auxiliary material used, for example starch, gelatin, gum arabic, silica, polyoxyethylene glycol, the solvent that liquid dosage form is used such as water, ethanol, propylene glycol, vegetables oil (as Semen Maydis oil, peanut oil, olive wet goods).Contain and also have other auxiliary material in the preparation of the compounds of this invention, tensio-active agent for example, lubricant, disintegrating agent, sanitas, correctives and pigment etc.The dosage that contains formula I compound of the present invention in tablet, capsule, Drug coating, injection and suppository is that the compound amount that exists in unit dosage form is calculated.The general content of the compounds of this invention is 0.01-5000mg in unit dosage form, and preferred unit dosage form contains 0.1-500mg, and preferred unit dosage form contains 1-300mg.Specifically, the present invention's solid dosage for oral administration that can provide comprises capsule, tablet, pill, powder and granule.In this type of solid dosage, active compound can be accepted vehicle or carrier such as Trisodium Citrate or Si Liaodengji dicalcium phosphate feed grade and/or following material with the medicine of at least a inertia and mix: a) weighting agent or extender; B) tackiness agent such as carboxymethyl cellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose and Sudan Gum-arabic; C) wetting Agent for Printing Inks such as glycerine; D) disintegrating agent such as agar, calcium carbonate, potato or tapioca (flour), Lalgine, some silicate and sodium carbonate; E) solution retarding agent such as paraffin; F) absorb accelerator such as quaternary ammonium compound; G) wetting agent such as hexadecanol and Zerol; H) sorbent material such as kaolin and wilkinite and i) lubricant such as talcum powder, calcium stearate, Magnesium Stearate, solid polyethylene glycol, sodium lauryl sulphate and their mixture.In the situation that capsule, tablet and pill also can comprise buffer reagent in described formulation.
The solids composition of similar type uses such as lactose and high molecular weight polyethylene glycol etc. of vehicle, also can be used as the weighting material in soft capsule and hard capsule.
The solid dosage of tablet, dragee (dragees), capsule, pill and granule can prepare together with dressing and shell material such as enteric coating material and known other clothing materials of field of medicine preparations.These solid dosages can be chosen wantonly and contain opalizer, and its composition also can make it just or preferentially choose wantonly with the delayed mode release of active ingredients at certain position of enteron aisle.The example of operable embedding composition comprises polymer substance and wax class.If be fit to, active compound also can be made into the micro-capsule form with one or more above-mentioned vehicle.
Liquid dosage form for oral administration comprises the acceptable emulsion of pharmacy, solution, suspensoid, syrup and elixir.Liquid dosage form also can contain this area inert diluent commonly used except containing the active ingredient beyond the region of objective existence, for example water or other solvents, solubilizing agent and emulsifying agent be ethanol, Virahol, ethyl-carbonate, ethyl acetate, benzylalcohol, peruscabin, propylene glycol, 1,3 butylene glycol, dimethyl formamide, oils (particularly Oleum Gossypii semen, peanut oil, Semen Maydis oil, germ oil, sweet oil, Viscotrol C and sesame oil), glycerine, tetrahydrofurfuryl alcohol, polyoxyethylene glycol and the fatty acid ester of sorbitan and their mixture for example.Oral compositions also can comprise auxiliary material except comprising inert diluent, for example wetting agent, emulsifying agent and suspension agent, sweeting agent, correctives and flavouring agent.
The composition of confession rectum or vagina administration is suppository preferably.Suppository can be by for example theobroma oil, polyoxyethylene glycol or suppository wax mix to prepare with the compounds of this invention and suitable non-irritating excipient or carrier, they are at room temperature solid, therefore but next at body temperature is liquid, can melt in rectal cavity or vaginal canal and discharges active compound.
The compounds of this invention and pharmaceutical composition thereof are also considered for topical.Comprise powder, sprays, ointment and inhalation for the local dosage form that gives the compounds of this invention.Under aseptic condition with active compound and pharmaceutically acceptable carrier and any required sanitas, buffer reagent or propellant mixing.Ophthalmic preparation, eye ointment, powder and solution also are considered within the scope of the present invention.
The compounds of this invention also can the liposome form administration.As known in the art, liposome makes with phosphatide or other lipid materials usually.Liposome is formed by the single or multiple lift aquation liquid crystal that is scattered in water-bearing media.Can accept on any nontoxic, physiology that can form liposome and metabolizable lipid all can use.The compounds of this invention of liposome form also can contain stablizer, sanitas, vehicle etc. except containing the compounds of this invention.Preferred lipid is natural and synthetic phosphatide and phosphatidylcholine (Yelkin TTS), and they can use separately or together.The method that forms liposome is well known in the art.Referring to for example Prescott, Ed., Methods in Cell Biology, Volume XIV, Academic Press, New York, N.Y. (1976), p.33.
The inventor is surprised to find, the compounds of this invention biology and/or physics and/or chemical aspect demonstrate challenging beneficial effect.
Description of drawings
Fig. 1 is the typical liquid chromatographic figure of the salt of preparation example 1 of the present invention.
Fig. 2 be the sodium salt of preparation example 2 of the present invention with the reference product silibinin through mixing the typical liquid chromatographic figure of gained mixture.
Embodiment
Further illustrate the present invention below by concrete Preparation Example and biological test example, still, should be understood to, these embodiment and test example are only used for the use that specifically describes more in detail, and should not be construed as for limiting in any form the present invention.
The present invention carries out generality and/or concrete description to the material and the test method that use in test.Although for to realize that many materials and working method that the object of the invention is used are well known in the art, the present invention still does to describe in detail as far as possible at this.It will be apparent to those skilled in the art that hereinafter, if do not specify, material therefor of the present invention and working method are well known in the art.
One, compound preparation example part
Preparation example 1: preparation the compounds of this invention, ester and sodium salt
(a) esterif iotacation step: the silibinin (commercially available product, chromatographic purity〉98.5%) of 1 molar part is dissolved in the pyridine of 2 times of weight, add the succinyl oxide of 3 molar part, stirring reaction is 20 hours at 40 ° of C temperature;
(b) hydrolysing step: add 75% ethanol of 2 times of volumes in step (a) the gained reaction solution, continue under 40 ° of C stirring reaction to hydrolysis fully; Be cooled to room temperature, add the ethyl acetate of 5M hydrochloric acid and 2 times of volumes of reaction solution of 1 times of volume of reaction solution, after surveying this mixture and be acidity with the pH test paper, add water, stir 15min, after standing demix, discard lower aqueous layer, organic layer washes with water, is neutral until water layer shows, standing demix, the organic layer decolorizing with activated carbon filters, and collects filtrate, desolventizing obtains silibinin 3-position hydroxyl and 12-position methylol and forms respectively the silybin bis-bias succinate of partial ester with succsinic acid;
(c) separating step: use the preparative liquid chromatography method to separate, be chromatograph packing material (10 μ m with octadecylsilane chemically bonded silica, brand is the C18 chromatograph packing material of Daiso SP-100-10-ODS-P) in the dynamic axial compression column preparative liquid chromatography system of packing into (the DAC-HB80 dynamic axial compression column system of Hanbon Sci. ﹠ Tech. Co., Ltd.), (with phosphoric acid adjust pH to 4.0)-methyl alcohol (50:50) is as moving phase take the 0.05mol/L sodium dihydrogen phosphate, and the detection wavelength is 288nm, step (b) products therefrom is dissolved with moving phase, use the sampling pump sample introduction, wash-out also records the extremely whole complete wash-outs of chromatographic peak of color atlas out, take the retention time of last chromatographic peak as benchmark, the intercepting relative retention time (comprises that namely relative retention time is 1.0 chromatographic peak and the elutriant of these three chromatographic peaks in front, peak at two chromatographic peaks out of wash-out between 0.4 ~ 0.7 and the elutriant that comprises altogether four chromatographic peaks of relative retention time wash-out two chromatographic peaks out between 0.7 ~ 1.0, when similar description is arranged in the context of the invention, all has identical meanings),
(d) extraction step: measure step (c) the gained elutriant of 1 volume to the separatory pan, then add the pure water of 1 volume, after mixing, then add the ethyl acetate of 1 volume, shaking out, standing demix discards lower floor's waste liquid; The upper strata ethyl acetate layer adds 1 volume pure water, shaking out, standing demix discards lower aqueous layer, so repeat 2 times or more than, ethyl acetate layer desolventizes in 40 ° of C rotary evaporations, 60 ° of C vacuum-dryings obtain silybin bis-bias succinate of the present invention (total recovery 95.6%, molar yield, lower same), C
33H
30O
16(M.W.682.60, calculated value: C=58.07%, H=4.43%, O=37.50%; Measured value C=58.06%, H=4.49%, O=37.45%).Further
(e) salify step: step (d) gained silybin bis-bias succinate is dissolved in dehydrated alcohol, add again sodium hydroxide-ethanol solution (silybin bis-bias succinate and sodium hydroxide mol ratio are 1:2.2), at room temperature stir and make reaction, Deng separating out white solid, filter, drying obtains Silybin dihemisuccinate disodium of the present invention (total recovery 94.2%).
Above step (e) gained salt mixes with 1 times of amount starch and 1 times of amount lactose, grinds to form and can be distributed in hard capsule by the fine powder of 100 mesh sieves, and every contains described salt 50mg, obtains the pharmaceutical composition of the present invention as capsule.In addition, above step (e) gained salt is mixed with 2 times of amount N.F,USP MANNITOL, dissolving to obtain solid content with suitable quantity of water is 20% solution, sterile filtration, preparation method according to injection lyophilize powder injection is prepared into freeze-dried powder, every bottle contains described salt 50mg, obtains the pharmaceutical composition of the present invention as freeze-dried powder injection.
Preparation example 2: preparation the compounds of this invention, ester and sodium salt
(a) esterif iotacation step: the silibinin (commercially available product) of 1 molar part is dissolved in the pyridine of 2 times of weight, add the succinyl oxide of 4 molar part, stirring reaction is 40 hours at 35 ° of C temperature;
(b) hydrolysing step: add 65% ethanol of 2 times of volumes in step (a) the gained reaction solution, continue under 35 ° of C stirring reaction to hydrolysis fully; Be cooled to room temperature, add the ethyl acetate of 2M hydrochloric acid and 2 times of volumes of reaction solution of 1 times of volume of reaction solution, survey this mixture to acidity with the pH test paper, add water, stir 60min, after standing demix, discard lower aqueous layer, organic layer washes with water, is neutral until water layer shows, standing demix, the organic layer decolorizing with activated carbon filters, and collects filtrate, desolventizing obtains silibinin 3-position hydroxyl and 12-position methylol and forms respectively the silybin bis-bias succinate of partial ester with succsinic acid;
(c) separating step: use the preparative liquid chromatography method to separate, be chromatograph packing material (10 μ m with octadecylsilane chemically bonded silica, brand is the C18 chromatograph packing material of Daiso SP-100-10-ODS-P) in the dynamic axial compression column preparative liquid chromatography system of packing into (the DAC-HB80 dynamic axial compression column system of Hanbon Sci. ﹠ Tech. Co., Ltd.), (with phosphoric acid adjust pH to 4.0)-methyl alcohol (50:50) is as moving phase take the 0.05mol/L sodium dihydrogen phosphate, and the detection wavelength is 288nm; Step (b) products therefrom is dissolved with moving phase, use the sampling pump sample introduction, wash-out also records the extremely whole complete wash-outs of chromatographic peak of color atlas out, take the retention time of last chromatographic peak as benchmark, the intercepting relative retention time is at two chromatographic peaks out of wash-out between 0.4 ~ 0.7 and the elutriant that comprises altogether four chromatographic peaks of relative retention time wash-out two chromatographic peaks out between 0.7 ~ 1.0;
(d) extraction step: measure step (c) the gained elutriant of 1 volume to the separatory pan, then add the pure water of 0.5 volume, after mixing, then add the ethyl acetate of 2 volumes, shaking out, standing demix discards lower floor's waste liquid; The upper strata ethyl acetate layer adds 1 volume pure water, shaking out, standing demix discards lower aqueous layer, so repeat 2 times or more than, ethyl acetate layer desolventizes in 35 ° of C rotary evaporations, 70 ° of C vacuum-dryings obtain silybin bis-bias succinate of the present invention, C
33H
30O
16(M.W.682.60, calculated value: C=58.07%, H=4.43%, O=37.50%; Measured value C=58.01%, H=4.46%, O=37.53%).Further
(e) salify step: step (d) gained silybin bis-bias succinate is dissolved in dehydrated alcohol, add again sodium hydroxide-ethanol solution (silybin bis-bias succinate and sodium hydroxide mol ratio are 1:2.2), at room temperature stir and make reaction, Deng separating out white solid, filter, drying obtains Silybin dihemisuccinate disodium of the present invention (total recovery 95.4%).
Preparation example 3: preparation the compounds of this invention, ester and sodium salt
(a) esterif iotacation step: the silibinin (commercially available product) of 1 molar part is dissolved in the pyridine of 2 times of weight, add the succinyl oxide of 2.5 molar part, stirring reaction is 15 hours at 50 ° of C temperature;
(b) hydrolysing step: add 85% ethanol of 2 times of volumes in step (a) the gained reaction solution, continue under 50 ° of C stirring reaction to hydrolysis fully; Be cooled to room temperature, add the ethyl acetate of 8M hydrochloric acid and 2 times of volumes of reaction solution of 1 times of volume of reaction solution, after surveying this mixture and be acidity with the pH test paper, add water, stir 5min, after standing demix, discard lower aqueous layer, organic layer washes with water, is neutral until water layer shows, standing demix, the organic layer decolorizing with activated carbon filters, and collects filtrate, desolventizing obtains silibinin 3-position hydroxyl and 12-position methylol and forms respectively the silybin bis-bias succinate of partial ester with succsinic acid;
(c) separating step: use the preparative liquid chromatography method to separate, be chromatograph packing material (10 μ m with octadecylsilane chemically bonded silica, brand is the C18 chromatograph packing material of Daiso SP-100-10-ODS-P) in the dynamic axial compression column preparative liquid chromatography system of packing into (the DAC-HB80 dynamic axial compression column system of Hanbon Sci. ﹠ Tech. Co., Ltd.), (with phosphoric acid adjust pH to 4.0)-methyl alcohol (50:50) is as moving phase take the 0.05mol/L sodium dihydrogen phosphate, and the detection wavelength is 288nm; Step (b) products therefrom is dissolved with moving phase, use the sampling pump sample introduction, wash-out also records the extremely whole complete wash-outs of chromatographic peak of color atlas out, take the retention time of last chromatographic peak as benchmark, the intercepting relative retention time is at two chromatographic peaks out of wash-out between 0.4 ~ 0.7 and the elutriant that comprises altogether four chromatographic peaks of relative retention time wash-out two chromatographic peaks out between 0.7 ~ 1.0;
(d) extraction step: measure step (c) the gained elutriant of 1 volume to the separatory pan, then add the pure water of 2 volumes, after mixing, then add the ethyl acetate of 0.5 volume, shaking out, standing demix discards lower floor's waste liquid; The upper strata ethyl acetate layer adds 1 volume pure water, shaking out, standing demix discards lower aqueous layer, so repeat 2 times or more than, ethyl acetate layer desolventizes in 50 ° of C rotary evaporations, 50 ° of C vacuum-dryings obtain silybin bis-bias succinate of the present invention, C
33H
30O
16(M.W.682.60, calculated value: C=58.07%, H=4.43%, O=37.50%; Measured value C=58.11%, H=4.43%, O=37.46%).Further
(e) salify step: step (d) gained silybin bis-bias succinate is dissolved in dehydrated alcohol, add again sodium hydroxide-ethanol solution (silybin bis-bias succinate and sodium hydroxide mol ratio are 1:2.2), at room temperature stir and make reaction, Deng separating out white solid, filter, drying obtains two Silybin dihemisuccinate disodiums (total recovery 94.8%) that X is sodium ion in formula I compound of the present invention.
Preparation example 4: preparation the compounds of this invention, sylvite
With reference to the method for preparation example 1, different is to use potassium hydroxide to carry out salify in step (e), obtains two silybin bis-bias succinate di-potassiums (total recovery 94.1%) that X is potassium ion in formula I compound of the present invention.
Reference examples 1: preparation reference material compound, ester and sodium salt
With reference to the method for preparation example 1, different is only the elutriant of intercepting relative retention time last chromatographic peak in wash-out two chromatographic peaks out between 0.4 ~ 0.7 in step (c).The product that obtains in step (d) is molecular weight M.W.=682.43 after measured; Obtain sodium salt product (in the present invention can referred to as Verbindung) in step (e).
Reference examples 2: preparation reference material compound, ester and sodium salt
With reference to the method for preparation example 1, different is only the elutriant of intercepting relative retention time rear chromatographic peak in wash-out two chromatographic peaks out between 0.4 ~ 0.7 in step (c).The product that obtains in step (d) is molecular weight M.W.=682.75 after measured; Obtain sodium salt product (in the present invention can referred to as compound f) in step (e).
Reference examples 3: preparation reference material compound, ester and sodium salt
Obtain silybin bis-bias succinate (molecular weight M.W.=682.71 after measured) according to GB2167414A embodiment 1 method, then obtain Silybin dihemisuccinate disodium according to GB2167414A embodiment 2 methods.
Reference examples 4: preparation reference material compound, sodium salt
Obtain silibinin succinate disodium (being Silybin dihemisuccinate disodium) according to CN101302212A embodiment 1 method.
Reference examples 5: preparation reference material compound, ester and sodium salt
With reference to the method for preparation example 1, different is only the elutriant of intercepting relative retention time last chromatographic peak in wash-out two chromatographic peaks out between 0.7 ~ 1.0 in step (c).The product that obtains in step (d) is molecular weight M.W.=682.43 after measured; Obtain sodium salt product (in the present invention can referred to as compound g) in step (e).
Reference examples 6: preparation reference material compound, ester and sodium salt
With reference to the method for preparation example 1, different is only the elutriant of intercepting relative retention time rear chromatographic peak in wash-out two chromatographic peaks out between 0.7 ~ 1.0 in step (c).The product that obtains in step (d) is molecular weight M.W.=682.75 after measured; Obtain sodium salt product (in the present invention can referred to as compound h) in step (e).
Commercially available reference substance:
(lot number: 1000007, its in the present invention can referred to as
), the Silybin dihemisuccinate disodium injection liquid that Madaus AG (MADAUS AG) produces, every bottle
The Silybin dihemisuccinate disodium (SDH) (silibinin that is equivalent to 350mg) that contains 528.5mg.
Above each preparation example and reference examples gained ester all have identical infrared spectra and 1H-NMR spectrum after measured, for example they all have the typical IR spectroscopic data of part (± 2cm-1) as follows:
Again for example they all to have the typical 1H-NMR spectrum of part data as follows:
| Chemistry ppm | Multiplicity | Proton number | Corresponding hydrogen atom |
| 2.3719～2.5803 | m | 8 | Succsinic acid-CH2- |
| 3.7775 | S | 3 | OCH3 |
| 4.9048～4.9648 | m | 2 | Proton on C27 |
| 5.5022～5.5147 | m | 1 | Proton on C12 |
| 5.5313～5.5436 | d | 1 | Proton on C13 |
| 5.8926-5.9033 | d | 1 | Proton on C2 |
| 5.9218-5.9250 | d | 1 | Proton on C3 |
| 5.9301-7.1593 | m | 9 | The phenyl ring proton |
| 10.9711-12.1976 | m | 2 | COOH |
In addition, with above each preparation example and reference examples gained ester and salt, (salt type compound is converted to their corresponding esters meter to be mixed with solution with methyl alcohol as solvent respectively, basic identical in each sample solution concentration of ester), carry out UV scanning in the scope of 200nm ~ 400nm, result shows that each sample all has identical ultra-violet absorption spectrum, all at 288nm, maximum absorption is arranged, and absorbancy roughly the same (differ each other and be no more than 10%, no matter be the form of ester or be sodium salt or the form of sylvite).Above result shows that above each preparation example and reference examples gained ester have identical chemical formula.
Two, compound inspection example part
Inspection example 1: high performance liquid chromatography (two appendix VD of Chinese Pharmacopoeia version in 2010) measuring method
(i) chromatographic condition and system suitability: be the chromatographic column of weighting agent with octadecylsilane chemically bonded silica, take 0.05mol/L sodium dihydrogen phosphate (with phosphoric acid adjust pH to 4.0)-methyl alcohol (50:50) as moving phase, the detection wavelength is 288nm, and column temperature is 30 ° of C; Get reference product silibinin (contrast grade, content is higher than 99%) appropriate, add moving phase and dissolve and dilute and make the solution that contains silibinin 200 μ g in every 1ml, as the reference product stock solution; Separately get this reference product stock solution and be diluted to the solution of 20 μ g/ml with moving phase, as system suitability solution, get this system suitability solution 20 μ l injection liquid chromatographies, record color atlas; Press out two main chromatographic peaks that A peak and B peak appear being referred to as in peak sequencing successively in this color atlas, adjust the retention time at A peak between 6-9min, and the resolution at A peak and B peak should be greater than 1.0; In the present invention, using 4.6 * 250mm, the C18 chromatographic column of 5 μ m, flow velocity is that 1.0ml/min can be easily be adjusted at the retention time at A peak between 6-9min, and the resolution at A peak and B peak should be greater than 1.5.In the present invention, in related HPLC chromatographic condition and system suitability, theoretical plate number is not less than 3000 by A peak calculating.
(ii) chromatographic purity and peak area ratio assay method: get for the sample (compound that obtains of preparation example of the present invention above, can be perhaps to add for example pharmaceutical composition that is mixed with of starch pharmaceutical preparation for example of appropriate amount of auxiliary materials with this compounds) appropriate (in the present invention, no matter test is ester or salt, during concrete operations, all can be converted to formula weight formula C
33H
30O
16(M.W.682.60) calculate), add moving phase and dissolve and make the solution that concentration is 0.5mg/ml, as need testing solution; Precision measures need testing solution 1ml, puts in the 100ml measuring bottle, is diluted to scale with moving phase, shakes up, in contrast solution; Method above adopting in " (i) chromatographic condition and system suitability " is got contrast solution 20 μ l injection liquid chromatographies, regulates detection sensitivity, makes the peak height of principal constituent H chromatographic peak be about 20% of full range; Precision measures need testing solution and each 20 μ l of contrast solution, difference injection liquid chromatography, record color atlas, press out four main chromatographic peaks that the first chromatographic peak (its in the present invention can referred to as E peak or E) and the second chromatographic peak (its in the present invention can referred to as F peak or F) and tertiary color spectrum peak (its in the present invention can referred to as G peak or G) and the 4th chromatographic peak (its in the present invention can referred to as H peak or H) appear being referred to as in peak sequencing successively in color atlas; Record color atlas to 2 times of H chromatographic peak retention time; In the need testing solution color atlas, any chromatographic peak less than 0.05 times of H chromatographic peak area in the contrast solution color atlas is ignored; Record peak area and each impurity peak area at main peak E peak in the need testing solution color atlas, F peak, G peak and H peak, the peak area sum at E peak, F peak, G peak and H peak is divided by whole percentage ratio of peak area sums, be the compounds of this invention chromatographic purity, can calculate respectively to get F peak, G peak and H peak and the peak-to-peak peak area ratio of E with the peak area at F peak, G peak, H peak divided by E peak-to-peak area respectively in addition;
(iii) mensuration of relative retention time (RRt): get for the sample (compound that obtains of preparation example of the present invention above, can be perhaps to add for example pharmaceutical composition that is mixed with of starch pharmaceutical preparation for example of appropriate amount of auxiliary materials with this compounds) appropriate (in the present invention, no matter test is ester or salt, during concrete operations, all can be converted to formula weight formula C
33H
30O
16(M.W.682.60) calculate), add moving phase and dissolve and make the solution that concentration is 0.5mg/ml, as the trial-product stock solution; Precision measures trial-product stock solution 1ml, puts in the 10ml measuring bottle, is diluted to scale with moving phase, shakes up, and makes to comprise the solution that the compounds of this invention concentration is about 50 μ g/ml, as trial-product test soln I; Another precision measure trial-product stock solution 1ml and (i) in the reference product stock solution 2.5ml of preparation, put in the 10ml measuring bottle, be diluted to scale with moving phase, shake up, make and comprise the solution that the compounds of this invention and reference product silibinin concentration are about respectively 50 μ g/ml, as trial-product test soln II; Precision measures the trial-product test soln II of 20 μ l, and the injection liquid chromatography records color atlas to 2 times of H chromatographic peak retention time; The retention time at four main chromatographic peak E peaks that record in color atlas two main chromatographic peak A peaks being produced by silibinin and B peak and produced by the compounds of this invention, F peak, G peak and H peak, be the relative retention time at E peak divided by the retention time at A peak with the retention time at E peak, be the relative retention time at F peak divided by the retention time at A peak with the retention time at F peak, be the relative retention time at G peak with the retention time at G peak divided by the retention time at A peak, be the relative retention time at H peak with the retention time at H peak divided by the retention time at A peak.
Have been found that auxiliary material can not affect test result in color atlas for gained capsule or lyophilized injectable powder in preparation example 1 of the present invention.
Inspection example 2:HPLC assay
In (i), (ii) of above inspection example 1, (iii), the retention time at A peak can easily be adjusted between 6-9min, and the resolution at A peak and B peak is greater than 1.2; A peak retention time is adjusted to approximately gone out the peak between 7.5 ~ 8min, the resolution at A peak and B peak approximately 1.6 ~ 2.
Use above method to obtain some performances of each preparation example product of the present invention and reference examples product as shown in the table:
In table, " * " expression perhaps can't be calculated relative retention time because only there being E, F, G or H single peak can't calculate peak-to-peak resolution; " ∞ " represents infinitely great, remove because the E peak does not exist that formula calculating causes.In addition, for reference examples 3 and 4 gained ester and/or salt, under dosing concentration identical with other sample, the peak area at G and H peak is significantly less than the peak area (75-85% about the corresponding peak of each preparation example at the corresponding peak of each preparation example, each formulation example respectively to contrast the peak basic identical, relevantly each other be no more than 5%).In table, " chromatographic purity, % " hurdle represents the chromatographic purity of main peak (relate to peak E, F, G, H or one of them); " peak area ratio " represents that the area at each peak is with respect to the multiple of E peak area.
Auxiliary material is on chromatographic separation and the impact of detection nothing in color atlas.
Fig. 1 is the typical liquid chromatographic figure of the salt of preparation example 1 of the present invention, show in figure that its chromatographic purity is very high, and the chromatographic separation effect is satisfactory.
Fig. 2 be the sodium salt of preparation example 2 of the present invention with the reference product silibinin through mixing the typical liquid chromatographic figure of gained mixture, in figure, silibinin forms two main chromatographic peak A peaks and B peak, A peak retention time is between 6-9min, and A peak and B peak resolution are greater than 1.5.Each chromatographic parameter sees the above table.In addition, the compounds of this invention (ester and/or salt) that obtains of preparation example 3 and preparation example 4 has typical collection of illustrative plates as depicted in figs. 1 and 2 equally basically.
Three, biological test example part
Biological test example 1: the provide protection of the compounds of this invention to liver injury due to α-amanita hemolysin
1, experiment purpose:
Try to achieve α-amanita hemolysin to the medial lethal dose (LD of kunming mice with the improvement karber's method
50), inject mouse with medial lethal dose, make it poisoning, research glossy ganoderma, silibinin, the various dose the compounds of this invention function of detoxification to poisoning mice.
2, experiment material:
α-amanita hemolysin, the chamber separation and purification of Hunan Normal University's fungal studies obtains, and purity is more than 95%; The compound that each preparation example of the present invention obtains; The compound or the commercially available product that obtain of each reference examples above; Silibinin, Sigma company, purity is more than 98%; Glossy ganoderma, changde, hunan medicinal fungi institute; Kunming kind small white mouse, Hunan Si Laike scape reach laboratory animal company limited to be provided, credit number: SCXK (Hunan) 2009-0004; AST, ALT measure test kit (reitman-frankel method), Shanghai Rongsheng Bioisystech Co., Ltd.
3, the improvement karber's method is measured LD
50Method:
Preliminary experiment: get healthy mice, about counterpoise 20g, be divided at random 3 groups, 3 every group, by the corresponding dosage abdominal injection of various dose group, every group of 0.4ml.Observed five days, and recorded the dead mouse situation.
LD
50Measure: with reference to the preliminary experiment result, according to certain agent distance, calculate gradient to the toxic agent amount.Get healthy mice, before experiment, fasting be can't help water 12 hours, was divided at random 4 groups, 10 every group, gave poison, every group of 0.4ml by the corresponding dosage difference abdominal injection of various dose group.Give the rear Continuous Observation of poison five days, record reaction and the death condition of mouse.
4, the provide protection research of several drugs to the amanita hemolysin poisoning mice
Pharmacological agent experiment: get healthy mice some, male and female half and half, indoor observation 3 days, room temperature 20-25 ℃.Before experiment, fasting be can't help water 12 hours.According to dosage regimen group hereinafter, random packet is set, 10 every group, equal male and female half and half.The per injection capacity is 0.4ml.The administration group is administration in 5 hours after envenoemation, was administered once every 6 hours later on, and one day four times.Simultaneously, normal group injecting normal saline every day four times is given poison for poisoning group for the first time, later per injection physiological saline, and envenoemation was put to death after 48 hours.
Biochemical Indices In Serum ALT, the mensuration of AST activity: press ALT, ALT and AST activity in mice serum are measured in the requirement of AST detection kit.
Statistical analysis: use excel software and carry out statistical procedures, measurement data all adopts X ± S to represent, organizes mean more and adopts variance analysis, and the significance of group difference adopts the T check.P=0.05 is the test of significance standard.
5, experimentation, results and analysis
(1) α-amanita hemolysin LD
50Mensuration
The preparation of amanita hemolysin solution: be prepared into the 1mg/ml mother liquor with distilled water dissolving amanita hemolysin standby.
LD
50Mensuration, carry out according to the acute toxicity test method (improvement karber's method) of " pharmacological experiment method ".
Preliminary experiment: poison was given in grouping according to the method described above, observes five days, records the dead mouse situation, and maximum dose level had death after 5 hours, and the second high dosage had the first dead at 21 hours.Result is as follows:
The abdominal injection amanita hemolysin is measured LD
50Trial test result (n=3)
LD
50Measure: according to the preliminary experiment result, dosage is set between 0.1mg/kg-2.5mg/kg, presses six groups of Geometric Sequence designs in this scope, common ratio (r) is obtained by following formula:
In formula, dosage during a=zero death rate, dosage during the b=100% mortality ratio, n=animal groups number.
Try to achieve r=1.90
The dosage of six groups is respectively 2.50,1.31,0.69,0.36,0.19,0.10mg/kg, four groups every group ten mouse in the middle of getting, and the abdominal injection amanita hemolysin operates according to aforesaid method.The maximum dose level group had death after 24 hours, 0.36 group occurred the first dead at 65 hours.Indivedual dead mouse process durations are long, even reach more than 12 hours.Poisoning darker person, slow in reacting, hair is fluffy, and is slow in action, rolls up at one.About dead front half an hour, mouse begins excitement, has the original place to spin, shake the head, and the symptoms such as tic, last whole body spasm is dead.Result such as following table:
Table: the abdominal injection amanita hemolysin is measured LD
50Experimental result (n=10)
| Injected dose (mg/kg) | ㏒d(X) | Dead animal number (N) | Mortality ratio (P) |
| 0.19 | -0.721 | 0 | 0 |
| 0.36 | -0.444 | 3 | 0.3 |
| 0.69 | -0.161 | 10 | 1.0 |
| 1.31 | 0.117 | 10 | 1.0 |
The Lethal Dose 50 LD of fatal goose cream
50Calculation result is as follows:
The logarithm of Xk=maximal dose, P is each group mortality ratio, expression decimally.
N is every treated animal number, is 10.
I=X
k-X
k-1=log
10d
4-log
10d
3=0.278
X
50＝X
k-i/2∑(P
n+P
n+1)＝-0.3556
So LD
50=log
10 -1(X
50)=0.45mg/kg.
(2) determining of amanita hemolysin (in the present invention can referred to as " goose cream ") envenoemation dosage: according to document and LD
50The result of data and this chamber pilot study selects 600 μ g/kg to test.
(3) preparation of animal grouping and tested medicine
Animal is divided into following each administration group:
Normal group (normal control, abdominal injection 0.9% physiological saline),
Poisoning group (abdominal injection amanita hemolysin, dosage 600 μ g/kg also can be described as " goose cream group "),
Glossy ganoderma group (abdominal injection, dosage 500mg/kg/ days),
Silibinin group (abdominal injection dosage 24.1mg/kg/ days, namely is equivalent to 0.05mmol/kg/ days),
Preparation example 1 ester group (abdominal injection, 34.1mg/kg/ days),
Preparation example 1 salt group (abdominal injection, 36.3mg/kg/ days),
Preparation example 2 ester groups (abdominal injection, 34.1mg/kg/ days),
Preparation example 2 salt groups (abdominal injection, 36.3mg/kg/ days),
Preparation example 3 salt groups (abdominal injection, 36.3mg/kg/ days),
Preparation example 4 salt groups (abdominal injection, 37.9mg/kg/ days),
Reference examples 1 salt group (abdominal injection, 36.3mg/kg/ days),
Reference examples 2 salt groups (abdominal injection, 36.3mg/kg/ days),
Reference examples 3 salt groups (abdominal injection, 36.3mg/kg/ days),
Reference examples 4 salt groups (abdominal injection, 36.3mg/kg/ days),
Reference examples 5 salt groups (abdominal injection, 36.3mg/kg/ days),
Reference examples 6 salt groups (abdominal injection, 36.3mg/kg/ days),
Commercially available product group (abdominal injection, 36.3mg/kg/ days).
Above each administration group dosage is all with wherein contained activeconstituents calculating.
The preparation of tested medicine: each medicine is all with 0.9% sodium chloride injection dissolving (all being dissolved state), glossy ganoderma is cream after processing, but do not affect injection, before per injection ultrasonic 10 minutes, it was 1.5ml that each medicine is mixed with the volume that suitable concentration makes every mouse per injection.
(4) experimentation: according to the method in experimental technique, carry out in order during per injection, if when namely injecting for the first time, normal group is first injection, and each time later on is also first injection, other group the like, guarantee that the time difference is consistent.Find that in process of the test the envenoemation mouse has the situation of having loose bowels to occur, and may affect gastro-intestinal system with amanita hemolysin relevant; After reduce gradually, possible mouse self has certain capacity of self-regulation.After envenoemation, 48 hours eyeballs are got blood, put to death mouse.
(5) the enzyme index detects: win eyeball of mouse with the operation on eyeball tweezers, blood centrifugal 10 minutes in 4000rpm is got supernatant, at first tries to achieve ALT and AST typical curve by the test kit explanation, is respectively y=0.0025x (R
2=0.9969) and y=0.002x (R
2=0.9616) (x is enzyme activity, and y is absorbancy).Try to achieve enzymic activity according to typical curve and the light absorption value that records again.Experimental result (providing with average) is as following table:
Table: the different reagent treatment poisoning rear ALT of amanita hemolysin and AST specific activity are
The poisoning rear ALT of animal and AST can obviously raise, have the glossy ganoderma and the silibinin that improve the toxicity symptom effect ALT and two indexs of AST are had obvious improvement, each preparation example reagent of the beat all the present invention of being has the good result of improving ALT and AST index; Salt and ester result are basic identical; Yet each reference examples is improved successful not as good as compound provided by the invention to ALT and two indexs of AST.Also measured in addition SOD (U/mgprot), CAT (U/gprot), three parameters of MDA (nmol/mgprot), result shows that the compounds of this invention has beat all good result equally aspect these indexs.
Claims (22)
1. compound, it is the combination of four kinds of isomer of following formula I compound:
Wherein each X represents hydrogen or metal ion independently of one another.
2. according to claim 1 compound, wherein said metal ion is alkalimetal ion or alkaline-earth metal ions; Perhaps, wherein X represents hydrogen, sodium ion, potassium ion, lithium ion, magnesium ion or calcium ion independently of one another.
3. the compound of according to claim 1 to 2 wherein comprises four kinds of isomer of formula I compound, and described four kinds of isomer account for more than 95% of this compound gross weight.
4. the compound of according to claim 1 to 3, according to high effective liquid chromatography for measuring, it presses out four main chromatographic peaks that the first chromatographic peak and the second chromatographic peak and tertiary color spectrum peak and the 4th chromatographic peak appear being referred to as in peak sequencing successively in color atlas, the peak area sum of described the first chromatographic peak and the second chromatographic peak and tertiary color spectrum peak and the 4th chromatographic peak accounts for more than 95% of total peak area.
5. the compound of according to claim 1 to 4, according to high effective liquid chromatography for measuring, it presses out four main chromatographic peaks that the first chromatographic peak and the second chromatographic peak and tertiary color spectrum peak and the 4th chromatographic peak appear being referred to as in peak sequencing successively in color atlas, wherein said the second chromatographic peak peak area is 0.5 ~ 1.5 times of described the first chromatographic peak peak area, described tertiary color spectrum peak-to-peak area is 4.5 ~ 13.5 times of described the first chromatographic peak peak area, and described the 4th chromatographic peak peak area is 4.5 ~ 13.5 times of described the first chromatographic peak peak area; Perhaps, described E peak, F peak, G peak, H peak peak area ratio is 1:(0.5 ~ 1.5): (4.5 ~ 13.5): (4.5 ~ 13.5).
6. according to claim 5 compound, wherein said the first chromatographic peak and the second chromatographic peak under described high effective liquid chromatography for measuring condition both resolution greater than 0.8; And/or, wherein said tertiary color spectrum peak and the 4th chromatographic peak under described high effective liquid chromatography for measuring condition both resolution greater than 1.0.
7. the compound of according to claim 1 to 6, wherein high performance liquid chromatography has and makes described the first chromatographic peak and the second chromatographic peak can reach resolution greater than 0.8 high effective liquid chromatography for measuring condition; And/or wherein high performance liquid chromatography has and makes described tertiary color spectrum peak and the 4th chromatographic peak can reach resolution greater than 1.0 high effective liquid chromatography for measuring condition.
8. the compound of according to claim 1 to 7, wherein said high effective liquid chromatography for measuring following by comprising " (i) chromatographic condition and system suitability " mode is carried out:
(i) chromatographic condition and system suitability: be the chromatographic column of weighting agent with octadecylsilane chemically bonded silica, take 0.05mol/L sodium dihydrogen phosphate (with phosphoric acid adjust pH to 4.0)-methyl alcohol (50:50) as moving phase, the detection wavelength is 288nm, and column temperature is 30 ° of C; Get the reference product silibinin appropriate, add moving phase and dissolve and dilute and make the solution that contains silibinin 200 μ g in every 1ml, as the reference product stock solution; Separately get this reference product stock solution and be diluted to the solution of 20 μ g/ml with moving phase, as system suitability solution, get this system suitability solution 20 μ l injection liquid chromatographies, record color atlas; Press out two main chromatographic peaks that A peak and B peak appear being referred to as in peak sequencing successively in this color atlas, the retention time at adjustment A peak is between 6-9min, and the resolution at A peak and B peak should be greater than 1.0 (for example greater than 1.2, for example greater than 1.5, for example greater than 2).
9. the compound of according to claim 1 to 8, wherein a representative instance following by comprising " (ii) chromatographic purity and the peak area ratio assay method " mode measured of chromatographic purity and peak area ratio is carried out:
(ii) chromatographic purity and peak area ratio assay method: get the compounds of this invention appropriate, add moving phase and dissolve and make the solution that concentration is 0.5mg/ml, as need testing solution; Precision measures 1ml, puts in the 100ml measuring bottle, is diluted to scale with moving phase, shakes up, in contrast solution; Adopt the method in (i) chromatographic condition of the present invention and system suitability, get contrast solution 20 μ l injection liquid chromatographies, regulate detection sensitivity, make the peak height of principal constituent H chromatographic peak be about 20% of full range; Precision measures need testing solution and each 20 μ l of contrast solution, and the injection liquid chromatography, record color atlas to 2 times of H chromatographic peak retention time respectively; In the need testing solution color atlas, any chromatographic peak less than 0.05 times of H chromatographic peak area in the contrast solution color atlas is ignored; Record peak area and each impurity peak area at main peak E peak in the need testing solution color atlas, F peak, G peak and H peak, the peak area sum at E peak, F peak, G peak and H peak is divided by whole percentage ratio of peak area sums, be the compounds of this invention chromatographic purity, can calculate respectively to get F peak, G peak and H peak and the peak-to-peak peak area ratio of E with the peak area at F peak, G peak and H peak divided by E peak-to-peak area respectively in addition.
10. the compound of according to claim 1 to 9, according to high effective liquid chromatography for measuring, take silibinin as reference product, and with the A peak of silibinin as the reference peak that calculates relative retention time, the relative retention time (RRt) of the first chromatographic peak of the compounds of this invention is 1.7 ~ 2.4, the relative retention time (RRt) of the second chromatographic peak of the compounds of this invention is 1.85 ~ 2.55, the relative retention time (RRt) that the tertiary color of the compounds of this invention is composed the peak is 2.4 ~ 3.2, the relative retention time (RRt) of the 4th chromatographic peak of the compounds of this invention is 2.8 ~ 3.6.
11. the compound of according to claim 1 to 10, according to high effective liquid chromatography for measuring, take silibinin as reference product, and with the A peak of silibinin as the reference peak that calculates relative retention time, the relative retention time (RRt) of the first chromatographic peak of the compounds of this invention is 1.7 ~ 2.4, the relative retention time (RRt) of the second chromatographic peak of the compounds of this invention is 1.85 ~ 2.55, the relative retention time (RRt) that the tertiary color of the compounds of this invention is composed the peak is 2.4 ~ 3.2, the relative retention time (RRt) of the 4th chromatographic peak of the compounds of this invention is 2.8 ~ 3.6, described high effective liquid chromatography for measuring relative retention time is by comprising what following mode was carried out:
(i) chromatographic condition and system suitability: be the chromatographic column of weighting agent with octadecylsilane chemically bonded silica, take 0.05mol/L sodium dihydrogen phosphate (with phosphoric acid adjust pH to 4.0)-methyl alcohol (50:50) as moving phase, the detection wavelength is 288nm, and column temperature is 30 ° of C; Get the reference product silibinin appropriate, add moving phase and dissolve and dilute and make the solution that contains silibinin 200 μ g in every 1ml, as the reference product stock solution; Separately get this reference product stock solution and be diluted to the solution of 20 μ g/ml with moving phase, as system suitability solution, get this system suitability solution 20 μ l injection liquid chromatographies, record color atlas; Press out two main chromatographic peaks that A peak and B peak appear being referred to as in peak sequencing successively in this color atlas, the retention time at adjustment A peak is between 6-9min, and the resolution at A peak and B peak should be greater than 1.0 (for example greater than 1.2, for example greater than 1.5, for example greater than 2);
(iii) mensuration of relative retention time (RRt): get the compounds of this invention appropriate, add moving phase and dissolve and make the solution that concentration is 0.5mg/ml, as the trial-product stock solution; Precision measures trial-product stock solution 1ml, puts in the 10ml measuring bottle, is diluted to scale with moving phase, shakes up, and makes to comprise the solution that the compounds of this invention concentration is about 50 μ g/ml, as trial-product test soln I; Another precision measures trial-product stock solution 1ml and reference product stock solution 2.5ml, put in the 10ml measuring bottle, be diluted to scale with moving phase, shake up, make and comprise the solution that the compounds of this invention and reference product silibinin concentration are about respectively 50 μ g/ml, as trial-product test soln II; Precision measures the trial-product test soln II of 20 μ l, and the injection liquid chromatography records color atlas to 2 times of H chromatographic peak retention time; The retention time at four main chromatographic peak E peaks that record in color atlas two main chromatographic peak A peaks being produced by silibinin and B peak and produced by the compounds of this invention, F peak, G peak and H peak, be the relative retention time at E peak divided by the retention time at A peak with the retention time at E peak, be the relative retention time at F peak divided by the retention time at A peak with the retention time at F peak, be the relative retention time at G peak with the retention time at G peak divided by the retention time at A peak, be the relative retention time at H peak with the retention time at H peak divided by the retention time at A peak.
12. the compound of according to claim 1 to 11, its be in following formula I compound by the combination of 12-position and the formed four kinds of isomer of 13-position chiral carbon:
Wherein each X represents hydrogen or metal ion independently of one another;
Described four kinds of isomer account for more than 95% of this compound gross weight, and perhaps the chromatographic purity of this compound is greater than 95%;
this compound is according to high effective liquid chromatography for measuring, press out four main chromatographic peaks that the first chromatographic peak and the second chromatographic peak and tertiary color spectrum peak and the 4th chromatographic peak appear being referred to as in peak sequencing successively in color atlas, described the first chromatographic peak and the second chromatographic peak resolution both are greater than 0.8, described tertiary color spectrum peak and the 4th chromatographic peak resolution both are greater than 1.0, and wherein said the second chromatographic peak peak area is 0.5 ~ 1.5 times of described the first chromatographic peak peak area, described tertiary color spectrum peak-to-peak area is 4.5 ~ 13.5 times of described the first chromatographic peak peak area, described the 4th chromatographic peak peak area is 4.5 ~ 13.5 times of described the first chromatographic peak peak area,
Described high effective liquid chromatography for measuring carries out as follows:
(i) chromatographic condition and system suitability: be the chromatographic column of weighting agent with octadecylsilane chemically bonded silica, take 0.05mol/L sodium dihydrogen phosphate (with phosphoric acid adjust pH to 4.0)-methyl alcohol (50:50) as moving phase, the detection wavelength is 288nm, and column temperature is 30 ° of C; Get the reference product silibinin appropriate, add moving phase and dissolve and dilute and make the solution that contains silibinin 200 μ g in every 1ml, as the reference product stock solution; Separately get this reference product stock solution and be diluted to the solution of 20 μ g/ml with moving phase, as system suitability solution, get this system suitability solution 20 μ l injection liquid chromatographies, record color atlas; Press out two main chromatographic peaks that A peak and B peak appear being referred to as in peak sequencing successively in this color atlas, adjust the retention time at A peak between 6-9min, and the resolution at A peak and B peak should be greater than 1.0;
(ii) chromatographic purity and peak area ratio assay method: get the compounds of this invention appropriate, add moving phase and dissolve and make the solution that concentration is 0.5mg/ml, as need testing solution; Precision measures 1ml, puts in the 100ml measuring bottle, is diluted to scale with moving phase, shakes up, in contrast solution; Adopt the method in (i) chromatographic condition of the present invention and system suitability, get contrast solution 20 μ l injection liquid chromatographies, regulate detection sensitivity, make the peak height of principal constituent H chromatographic peak be about 20% of full range; Precision measures need testing solution and each 20 μ l of contrast solution, and the injection liquid chromatography, record color atlas to 2 times of H chromatographic peak retention time respectively; In the need testing solution color atlas, any chromatographic peak less than 0.05 times of H chromatographic peak area in the contrast solution color atlas is ignored; Record peak area and each impurity peak area at main peak E peak in the need testing solution color atlas, F peak, G peak and H peak, the peak area sum at E peak, F peak, G peak and H peak is divided by whole percentage ratio of peak area sums, be the compounds of this invention chromatographic purity, can calculate respectively to get F peak, G peak and H peak and the peak-to-peak peak area ratio of E with the peak area at F peak, G peak, H peak divided by E peak-to-peak area respectively in addition.
13. the compound of according to claim 1 to 12, its be in following formula I compound by the combination of 12-position and the formed four kinds of isomer of 13-position chiral carbon:
Wherein each X represents hydrogen or metal ion independently of one another;
Described four kinds of isomer account for more than 95% of this compound gross weight, and perhaps the chromatographic purity of this compound is greater than 95%;
This compound presses out according to high effective liquid chromatography for measuring four main chromatographic peaks that the first chromatographic peak and the second chromatographic peak and tertiary color spectrum peak and the 4th chromatographic peak appear being referred to as in peak sequencing successively in color atlas;
This compound is according to high effective liquid chromatography for measuring, take silibinin as reference product, and with the A peak of silibinin as the reference peak that calculates relative retention time, the relative retention time (RRt) of the first chromatographic peak of this compound is 1.7 ~ 2.4, the relative retention time (RRt) of the second chromatographic peak of this compound is 1.85 ~ 2.55, the relative retention time (RRt) that the tertiary color of this compound is composed the peak is 2.4 ~ 3.2, and the relative retention time (RRt) of the 4th chromatographic peak of this compound is 2.8 ~ 3.6;
Described high effective liquid chromatography for measuring carries out as follows:
(i) chromatographic condition and system suitability: be the chromatographic column of weighting agent with octadecylsilane chemically bonded silica, take 0.05mol/L sodium dihydrogen phosphate (with phosphoric acid adjust pH to 4.0)-methyl alcohol (50:50) as moving phase, the detection wavelength is 288nm, and column temperature is 30 ° of C; Get the reference product silibinin appropriate, add moving phase and dissolve and dilute and make the solution that contains silibinin 200 μ g in every 1ml, as the reference product stock solution; Separately get this reference product stock solution and be diluted to the solution of 20 μ g/ml with moving phase, as system suitability solution, get this system suitability solution 20 μ l injection liquid chromatographies, record color atlas; Press out two main chromatographic peaks that A peak and B peak appear being referred to as in peak sequencing successively in this color atlas, adjust the retention time at A peak between 6-9min, and the resolution at A peak and B peak should be greater than 1.0;
(iii) mensuration of relative retention time (RRt): get the compounds of this invention appropriate, add moving phase and dissolve and make the solution that concentration is 0.5mg/ml, as the trial-product stock solution; Precision measures trial-product stock solution 1ml, puts in the 10ml measuring bottle, is diluted to scale with moving phase, shakes up, and makes to comprise the solution that the compounds of this invention concentration is about 50 μ g/ml, as trial-product test soln I; Another precision measures trial-product stock solution 1ml and reference product stock solution 2.5ml, put in the 10ml measuring bottle, be diluted to scale with moving phase, shake up, make and comprise the solution that the compounds of this invention and reference product silibinin concentration are about respectively 50 μ g/ml, as trial-product test soln II; Precision measures the trial-product test soln II of 20 μ l, and the injection liquid chromatography records color atlas to 2 times of H chromatographic peak retention time; The retention time at four main chromatographic peak E peaks that record in color atlas two main chromatographic peak A peaks being produced by silibinin and B peak and produced by the compounds of this invention, F peak, G peak and H peak, be the relative retention time at E peak divided by the retention time at A peak with the retention time at E peak, be the relative retention time at F peak divided by the retention time at A peak with the retention time at F peak, be the relative retention time at G peak with the retention time at G peak divided by the retention time at A peak, be the relative retention time at H peak with the retention time at H peak divided by the retention time at A peak.
14. the compound of according to claim 1 to 13, its be in following formula I compound by the combination of 12-position and the formed four kinds of isomer of 13-position chiral carbon:
Wherein each X represents hydrogen or metal ion independently of one another;
Described four kinds of isomer account for more than 95% of this compound gross weight, and perhaps the chromatographic purity of this compound is greater than 95%;
This compound presses out according to high effective liquid chromatography for measuring four main chromatographic peaks that the first chromatographic peak and the second chromatographic peak and tertiary color spectrum peak and the 4th chromatographic peak appear being referred to as in peak sequencing successively in color atlas;
Described the first chromatographic peak and the second chromatographic peak resolution both are greater than 0.8, and wherein said the second chromatographic peak peak area is 0.5 ~ 1.5 times of described the first chromatographic peak peak area; Described tertiary color spectrum peak and the 4th chromatographic peak resolution both are greater than 1.0, and wherein said tertiary color spectrum peak-to-peak area is 4.5 ~ 13.5 times of described the first chromatographic peak peak area, and described the 4th chromatographic peak peak area is 4.5 ~ 13.5 times of described the first chromatographic peak peak area;
This compound is according to high effective liquid chromatography for measuring, take silibinin as reference product, and with the A peak of silibinin as the reference peak that calculates relative retention time, the relative retention time (RRt) of the first chromatographic peak of this compound is 1.7 ~ 2.4, the relative retention time (RRt) of the second chromatographic peak of this compound is 1.85 ~ 2.55, the relative retention time (RRt) that the tertiary color of this compound is composed the peak is 2.4 ~ 3.2, and the relative retention time (RRt) of the 4th chromatographic peak of this compound is 2.8 ~ 3.6;
Described high effective liquid chromatography for measuring carries out as follows:
(i) chromatographic condition and system suitability: be the chromatographic column of weighting agent with octadecylsilane chemically bonded silica, take 0.05mol/L sodium dihydrogen phosphate (with phosphoric acid adjust pH to 4.0)-methyl alcohol (50:50) as moving phase, the detection wavelength is 288nm, and column temperature is 30 ° of C; Get the reference product silibinin appropriate, add moving phase and dissolve and dilute and make the solution that contains silibinin 200 μ g in every 1ml, as the reference product stock solution; Separately get this reference product stock solution and be diluted to the solution of 20 μ g/ml with moving phase, as system suitability solution, get this system suitability solution 20 μ l injection liquid chromatographies, record color atlas; Press out two main chromatographic peaks that A peak and B peak appear being referred to as in peak sequencing successively in this color atlas, adjust the retention time at A peak between 6-9min, and the resolution at A peak and B peak should be greater than 1.0;
(ii) chromatographic purity and peak area ratio assay method: get the compounds of this invention appropriate, add moving phase and dissolve and make the solution that concentration is 0.5mg/ml, as need testing solution; Precision measures 1ml, puts in the 100ml measuring bottle, is diluted to scale with moving phase, shakes up, in contrast solution; Adopt the method in (i) chromatographic condition of the present invention and system suitability, get contrast solution 20 μ l injection liquid chromatographies, regulate detection sensitivity, make the peak height of principal constituent H chromatographic peak be about 20% of full range; Precision measures need testing solution and each 20 μ l of contrast solution, and the injection liquid chromatography, record color atlas to 2 times of H chromatographic peak retention time respectively; In the need testing solution color atlas, any chromatographic peak less than 0.05 times of H chromatographic peak area in the contrast solution color atlas is ignored; Record peak area and each impurity peak area at main peak E peak in the need testing solution color atlas, F peak, G peak and H peak, the peak area sum at E peak, F peak, G peak and H peak is divided by whole percentage ratio of peak area sums, be the compounds of this invention chromatographic purity, can calculate respectively to get F peak, G peak and H peak and the peak-to-peak peak area ratio of E with the peak area at F peak, G peak, H peak divided by E peak-to-peak area respectively in addition;
(iii) mensuration of relative retention time (RRt): get the compounds of this invention appropriate, add moving phase and dissolve and make the solution that concentration is 0.5mg/ml, as the trial-product stock solution; Precision measures trial-product stock solution 1ml, puts in the 10ml measuring bottle, is diluted to scale with moving phase, shakes up, and makes to comprise the solution that the compounds of this invention concentration is about 50 μ g/ml, as trial-product test soln I; Another precision measures trial-product stock solution 1ml and reference product stock solution 2.5ml, put in the 10ml measuring bottle, be diluted to scale with moving phase, shake up, make and comprise the solution that the compounds of this invention and reference product silibinin concentration are about respectively 50 μ g/ml, as trial-product test soln II; Precision measures the trial-product test soln II of 20 μ l, and the injection liquid chromatography records color atlas to 2 times of H chromatographic peak retention time; The retention time at four main chromatographic peak E peaks that record in color atlas two main chromatographic peak A peaks being produced by silibinin and B peak and produced by the compounds of this invention, F peak, G peak and H peak, be the relative retention time at E peak divided by the retention time at A peak with the retention time at E peak, be the relative retention time at F peak divided by the retention time at A peak with the retention time at F peak, be the relative retention time at G peak with the retention time at G peak divided by the retention time at A peak, be the relative retention time at H peak with the retention time at H peak divided by the retention time at A peak.
15. a pharmaceutical composition wherein comprises the described compound of claim 1-14 any one and optional pharmaceutical excipient.
16. pharmaceutical composition according to claim 15, wherein comprise as in the following formula I compound of activeconstituents by 12-position and the 13-formed four kinds of isomer of position chiral carbon and optional pharmaceutical excipient:
Wherein each X represents hydrogen or metal ion independently of one another;
This pharmaceutical composition is according to high effective liquid chromatography for measuring, disregard the auxiliary material chromatographic peak, press out four main chromatographic peaks that the first chromatographic peak and the second chromatographic peak and tertiary color spectrum peak and the 4th chromatographic peak appear being referred to as in peak sequencing successively in color atlas, described the first chromatographic peak and the second chromatographic peak resolution both are greater than 0.8, and wherein said the second chromatographic peak peak area is 0.5 ~ 1.5 times of described the first chromatographic peak peak area; Described tertiary color spectrum peak and the 4th chromatographic peak resolution both are greater than 1.0, and wherein said tertiary color spectrum peak-to-peak area is 4.5 ~ 13.5 times of described the first chromatographic peak peak area, and described the 4th chromatographic peak peak area is 4.5 ~ 13.5 times of described the first chromatographic peak peak area;
Described high effective liquid chromatography for measuring carries out as follows:
(i) chromatographic condition and system suitability: be the chromatographic column of weighting agent with octadecylsilane chemically bonded silica, take 0.05mol/L sodium dihydrogen phosphate (with phosphoric acid adjust pH to 4.0)-methyl alcohol (50:50) as moving phase, the detection wavelength is 288nm, and column temperature is 30 ° of C; Get the reference product silibinin appropriate, add moving phase and dissolve and dilute and make the solution that contains silibinin 200 μ g in every 1ml, as the reference product stock solution; Separately get this reference product stock solution and be diluted to the solution of 20 μ g/ml with moving phase, as system suitability solution, get this system suitability solution 20 μ l injection liquid chromatographies, record color atlas; Press out two main chromatographic peaks that A peak and B peak appear being referred to as in peak sequencing successively in this color atlas, adjust the retention time at A peak between 6-9min, and the resolution at A peak and B peak should be greater than 1.0;
(ii) chromatographic purity and peak area ratio assay method: get pharmaceutical composition of the present invention appropriate, add moving phase and dissolve and make that to contain formula I compound concentration be the solution of 0.5mg/ml, as need testing solution; Precision measures 1ml, puts in the 100ml measuring bottle, is diluted to scale with moving phase, shakes up, in contrast solution; Adopt the method in (i) chromatographic condition of the present invention and system suitability, get contrast solution 20 μ l injection liquid chromatographies, regulate detection sensitivity, make the peak height of principal constituent H chromatographic peak be about 20% of full range; Precision measures need testing solution and each 20 μ l of contrast solution, and the injection liquid chromatography, record color atlas to 2 times of H chromatographic peak retention time respectively; In the need testing solution color atlas, any chromatographic peak less than 0.05 times of H chromatographic peak area in the contrast solution color atlas is ignored, and also ignores in the auxiliary material peak; Record peak area and each impurity peak area at main peak E peak in the need testing solution color atlas, F peak, G peak and H peak, the peak area sum at E peak, F peak, G peak and H peak is divided by whole percentage ratio of peak area sums, be pharmaceutical composition chromatographic purity of the present invention, can calculate respectively to get F peak, G peak and H peak and the peak-to-peak peak area ratio of E with the peak area at F peak, G peak, H peak divided by E peak-to-peak area respectively in addition.
17. the pharmaceutical composition according to claim 15 to 16, wherein comprise as in the following formula I compound of activeconstituents by 12-position and the 13-formed four kinds of isomer of position chiral carbon and optional pharmaceutical excipient:
Wherein each X represents hydrogen or metal ion independently of one another;
This pharmaceutical composition is disregarded the auxiliary material chromatographic peak according to high effective liquid chromatography for measuring, presses out four main chromatographic peaks that the first chromatographic peak and the second chromatographic peak and tertiary color spectrum peak and the 4th chromatographic peak appear being referred to as in peak sequencing successively in color atlas;
This pharmaceutical composition is according to high effective liquid chromatography for measuring, take silibinin as reference product, and with the A peak of silibinin as the reference peak that calculates relative retention time, the relative retention time (RRt) of the first chromatographic peak of this pharmaceutical composition is 1.7 ~ 2.4, the relative retention time (RRt) of the second chromatographic peak of this pharmaceutical composition is 1.85 ~ 2.55, the relative retention time (RRt) that the tertiary color of this pharmaceutical composition is composed the peak is 2.4 ~ 3.2, and the relative retention time (RRt) of the 4th chromatographic peak of this pharmaceutical composition is 2.8 ~ 3.6;
Described high effective liquid chromatography for measuring carries out as follows:
(i) chromatographic condition and system suitability: be the chromatographic column of weighting agent with octadecylsilane chemically bonded silica, take 0.05mol/L sodium dihydrogen phosphate (with phosphoric acid adjust pH to 4.0)-methyl alcohol (50:50) as moving phase, the detection wavelength is 288nm, and column temperature is 30 ° of C; Get the reference product silibinin appropriate, add moving phase and dissolve and dilute and make the solution that contains silibinin 200 μ g in every 1ml, as the reference product stock solution; Separately get this reference product stock solution and be diluted to the solution of 20 μ g/ml with moving phase, as system suitability solution, get this system suitability solution 20 μ l injection liquid chromatographies, record color atlas; Press out two main chromatographic peaks that A peak and B peak appear being referred to as in peak sequencing successively in this color atlas, adjust the retention time at A peak between 6-9min, and the resolution at A peak and B peak should be greater than 1.0;
(iii) mensuration of relative retention time (RRt): get pharmaceutical composition of the present invention appropriate, add moving phase and dissolve and make that to contain formula I compound concentration be the solution of 0.5mg/ml, as the trial-product stock solution; Precision measures trial-product stock solution 1ml, puts in the 10ml measuring bottle, is diluted to scale with moving phase, shakes up, and makes to comprise to contain the solution that formula I compound concentration is about 50 μ g/ml, as trial-product test soln I; Another precision measures trial-product stock solution 1ml and reference product stock solution 2.5ml, put in the 10ml measuring bottle, be diluted to scale with moving phase, shake up, make to comprise and contain the solution that formula I compound and reference product silibinin concentration are about respectively 50 μ g/ml, as trial-product test soln II; Precision measures the trial-product test soln II of 20 μ l, and the injection liquid chromatography records color atlas to 2 times of H chromatographic peak retention time; Record in color atlas two main chromatographic peak A peaks being produced by silibinin and B peak and by the retention time at four main chromatographic peak E peaks of drug regimen deposits yields of the present invention, F peak, G peak and H peak, be the relative retention time at E peak divided by the retention time at A peak with the retention time at E peak, be the relative retention time at F peak divided by the retention time at A peak with the retention time at F peak, be the relative retention time at G peak with the retention time at G peak divided by the retention time at A peak, be the relative retention time at H peak with the retention time at H peak divided by the retention time at A peak.
18. the pharmaceutical composition according to claim 15 to 17, wherein comprise as in the following formula I compound of activeconstituents by 12-position and the 13-formed four kinds of isomer of position chiral carbon and optional pharmaceutical excipient:
Wherein each X represents hydrogen or metal ion independently of one another;
This pharmaceutical composition is disregarded the auxiliary material chromatographic peak according to high effective liquid chromatography for measuring, presses out four main chromatographic peaks that the first chromatographic peak and the second chromatographic peak and tertiary color spectrum peak and the 4th chromatographic peak appear being referred to as in peak sequencing successively in color atlas;
Described the first chromatographic peak and the second chromatographic peak resolution both are greater than 0.8, and wherein said the second chromatographic peak peak area is 0.5 ~ 1.5 times of described the first chromatographic peak peak area; Described tertiary color spectrum peak and the 4th chromatographic peak resolution both are greater than 1.0, and wherein said tertiary color spectrum peak-to-peak area is 4.5 ~ 13.5 times of described the first chromatographic peak peak area, and described the 4th chromatographic peak peak area is 4.5 ~ 13.5 times of described the first chromatographic peak peak area;
This pharmaceutical composition is according to high effective liquid chromatography for measuring, take silibinin as reference product, and with the A peak of silibinin as the reference peak that calculates relative retention time, the relative retention time (RRt) of the first chromatographic peak of this pharmaceutical composition is 1.7 ~ 2.4, the relative retention time (RRt) of the second chromatographic peak of this pharmaceutical composition is 1.85 ~ 2.55, the relative retention time (RRt) that the tertiary color of this pharmaceutical composition is composed the peak is 2.4 ~ 3.2, and the relative retention time (RRt) of the 4th chromatographic peak of this pharmaceutical composition is 2.8 ~ 3.6;
Described high effective liquid chromatography for measuring carries out as follows:
(i) chromatographic condition and system suitability: be the chromatographic column of weighting agent with octadecylsilane chemically bonded silica, take 0.05mol/L sodium dihydrogen phosphate (with phosphoric acid adjust pH to 4.0)-methyl alcohol (50:50) as moving phase, the detection wavelength is 288nm, and column temperature is 30 ° of C; Get the reference product silibinin appropriate, add moving phase and dissolve and dilute and make the solution that contains silibinin 200 μ g in every 1ml, as the reference product stock solution; Separately get this reference product stock solution and be diluted to the solution of 20 μ g/ml with moving phase, as system suitability solution, get this system suitability solution 20 μ l injection liquid chromatographies, record color atlas; Press out two main chromatographic peaks that A peak and B peak appear being referred to as in peak sequencing successively in this color atlas, adjust the retention time at A peak between 6-9min, and the resolution at A peak and B peak should be greater than 1.0;
(ii) chromatographic purity and peak area ratio assay method: get pharmaceutical composition of the present invention appropriate, add moving phase and dissolve and make that to contain formula I compound concentration be the solution of 0.5mg/ml, as need testing solution; Precision measures 1ml, puts in the 100ml measuring bottle, is diluted to scale with moving phase, shakes up, in contrast solution; Adopt the method in (i) chromatographic condition of the present invention and system suitability, get contrast solution 20 μ l injection liquid chromatographies, regulate detection sensitivity, make the peak height of principal constituent H chromatographic peak be about 20% of full range; Precision measures need testing solution and each 20 μ l of contrast solution, and the injection liquid chromatography, record color atlas to 2 times of H chromatographic peak retention time respectively; In the need testing solution color atlas, any chromatographic peak less than 0.05 times of H chromatographic peak area in the contrast solution color atlas is ignored, and also ignores in the auxiliary material peak; Record peak area and each impurity peak area at main peak E peak in the need testing solution color atlas, F peak, G peak and H peak, the peak area sum at E peak, F peak, G peak and H peak is divided by whole percentage ratio of peak area sums, be pharmaceutical composition chromatographic purity of the present invention, can calculate respectively to get F peak, G peak and H peak and the peak-to-peak peak area ratio of E with the peak area at F peak, G peak, H peak divided by E peak-to-peak area respectively in addition;
(iii) mensuration of relative retention time (RRt): get pharmaceutical composition of the present invention appropriate, add moving phase and dissolve and make that to contain formula I compound concentration be the solution of 0.5mg/ml, as the trial-product stock solution; Precision measures trial-product stock solution 1ml, puts in the 10ml measuring bottle, is diluted to scale with moving phase, shakes up, and makes to comprise to contain the solution that formula I compound concentration is about 50 μ g/ml, as trial-product test soln I; Another precision measures trial-product stock solution 1ml and reference product stock solution 2.5ml, put in the 10ml measuring bottle, be diluted to scale with moving phase, shake up, make to comprise and contain the solution that formula I compound and reference product silibinin concentration are about respectively 50 μ g/ml, as trial-product test soln II; Precision measures the trial-product test soln II of 20 μ l, and the injection liquid chromatography records color atlas to 2 times of H chromatographic peak retention time; Record in color atlas two main chromatographic peak A peaks being produced by silibinin and B peak and by the retention time at four main chromatographic peak E peaks of drug regimen deposits yields of the present invention, F peak, G peak and H peak, be the relative retention time at E peak divided by the retention time at A peak with the retention time at E peak, be the relative retention time at F peak divided by the retention time at A peak with the retention time at F peak, be the relative retention time at G peak with the retention time at G peak divided by the retention time at A peak, be the relative retention time at H peak with the retention time at H peak divided by the retention time at A peak.
19. the pharmaceutical composition according to claim 15 to 18, it is according to high effective liquid chromatography for measuring, disregard the auxiliary material chromatographic peak, press out four main chromatographic peaks that the first chromatographic peak and the second chromatographic peak and tertiary color spectrum peak and the 4th chromatographic peak appear being referred to as in peak sequencing successively in color atlas, the peak area sum of described the first chromatographic peak, the second chromatographic peak, tertiary color spectrum peak and the 4th chromatographic peak accounts for more than 95% of total peak area.
20. prepare the method for the described compound of claim 1 to 14 any one, it comprises the following steps:
(a) esterif iotacation step: make silibinin shown in following formula:
Dissolve in suitable organic solvent, add succinyl oxide, in 5 ~ 50 hours (for example 10 ~ 40 hours, for example 15 ~ 30 hours) of the lower reaction of 30 ~ 80 ° of C temperature (for example 35 ~ 50 ° of C);
(b) hydrolysing step: add appropriate 50 ~ 90% ethanol (for example 65 ~ 85% ethanol) in step (a) gained reaction solution, continue at the lower stirring reaction of 30 ~ 80 ° of C temperature (for example 35 ~ 50 ° of C) complete to hydrolysis; Be cooled to room temperature, add that 2 ~ 8mol/L hydrochloric acid is appropriate and ethyl acetate is appropriate, after surveying this mixture and be acidity with the pH test paper, add water, stir 5 ~ 60min, after standing demix, discard lower aqueous layer, organic layer washes with water, is neutral until water layer shows, standing demix, the organic layer decolorizing with activated carbon filters, and collects filtrate, desolventizing obtains silibinin 3-position hydroxyl and 12-position methylol and forms silybin bis-bias succinate shown in the following formula of partial ester with succsinic acid respectively:
(c) separating step: use the preparative liquid chromatography method to separate, be that (for example packing material size is 10 μ m to chromatograph packing material with octadecylsilane chemically bonded silica, can be for example that brand is the C18 chromatograph packing material of Daiso SP-100-10-ODS-P) in the dynamic axial compression column preparative liquid chromatography system of packing into (can be for example the DAC-HB80 dynamic axial compression column system of Hanbon Sci. ﹠ Tech. Co., Ltd.), take 0.05mol/L sodium dihydrogen phosphate (with phosphoric acid adjust pH to 4.0)-methyl alcohol (50:50) as moving phase, the detection wavelength is 288nm, step (b) products therefrom is dissolved with moving phase, use the sampling pump sample introduction, wash-out also records the extremely whole complete wash-outs of chromatographic peak of color atlas out, take the retention time of last chromatographic peak as benchmark, the intercepting relative retention time is at two chromatographic peaks out of wash-out between 0.4 ~ 0.7 and the elutriant that comprises altogether four chromatographic peaks of relative retention time wash-out two chromatographic peaks out between 0.7 ~ 1.0,
(d) extraction step: measure step (c) the gained elutriant of 1 volume to the separatory pan, then add the pure water of 0.5 ~ 2 volume, after mixing, then add the ethyl acetate of 0.5 ~ 2 volume, shaking out, standing demix discards lower floor's waste liquid; The upper strata ethyl acetate layer adds 0.5 ~ 2 volume pure water, shaking out, standing demix, discard lower aqueous layer, so repeat 2 times or more than, ethyl acetate layer is in 30 ~ 50 ° of C desolventizings (for example 35-50 ° of C, for example approximately 40 ° of C rotary evaporations desolventize), dry (for example in 50 ~ 70 ° of C vacuum-dryings) obtain silybin bis-bias succinate; With optional
(e) salify step: step (d) gained silybin bis-bias succinate is dissolved in organic solvent (for example methyl alcohol, dehydrated alcohol), the solution (for example being dissolved in the solution in organic solvent (for example methyl alcohol, dehydrated alcohol)) that adds again alkali metal hydroxide or alkaline earth metal hydroxides, stirring makes reaction, separate out white solid, filter, drying obtains an alkali metal salt or the alkaline earth salt of silybin bis-bias succinate.
21. the described compound of claim 1 to 14 any one is for the preparation of the purposes in the medicine for the treatment of, improvement or prevention of liver disease.
22. purposes according to claim 21, wherein said hepatic diseases is selected from: because of the Acute Hepatic that Amanita phalloides causes poisoning, acute, chronic hepatitis, first cirrhosis, toxic hepatitis, dysfunction of liver due to fatty liver, dysfunction of liver due to alcoholic liver.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310057065.5A CN103113359B (en) | 2013-02-22 | 2013-02-22 | Silybin bis-bias succinate and pharmaceutical salts thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310057065.5A CN103113359B (en) | 2013-02-22 | 2013-02-22 | Silybin bis-bias succinate and pharmaceutical salts thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103113359A true CN103113359A (en) | 2013-05-22 |
| CN103113359B CN103113359B (en) | 2016-01-06 |
Family
ID=48411779
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310057065.5A Active CN103113359B (en) | 2013-02-22 | 2013-02-22 | Silybin bis-bias succinate and pharmaceutical salts thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103113359B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109580818A (en) * | 2018-12-14 | 2019-04-05 | 江西省农业科学院农产品质量安全与标准研究所 | A method of Florfenicol drug residue in detection pig hair |
| CN110183431A (en) * | 2018-06-09 | 2019-08-30 | 江苏新元素医药科技有限公司 | One kind is for liver disease or the compound of prevention |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES481754A3 (en) * | 1979-06-21 | 1980-03-01 | Madaus Cerafarm Lab | Procedure for the preparation of silicine acid hemisuccinates. (Machine-translation by Google Translate, not legally binding) |
| GB2167414A (en) * | 1984-11-22 | 1986-05-29 | Madaus & Co Dr | Silibinin derivatives |
| CN101302212A (en) * | 2008-07-04 | 2008-11-12 | 山东省医药工业研究所 | Preparation and use of silybum marianum di-partial succinate and salt thereof |
-
2013
- 2013-02-22 CN CN201310057065.5A patent/CN103113359B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES481754A3 (en) * | 1979-06-21 | 1980-03-01 | Madaus Cerafarm Lab | Procedure for the preparation of silicine acid hemisuccinates. (Machine-translation by Google Translate, not legally binding) |
| GB2167414A (en) * | 1984-11-22 | 1986-05-29 | Madaus & Co Dr | Silibinin derivatives |
| CN101302212A (en) * | 2008-07-04 | 2008-11-12 | 山东省医药工业研究所 | Preparation and use of silybum marianum di-partial succinate and salt thereof |
Non-Patent Citations (1)
| Title |
|---|
| LURDES MIRA ET AL.: "Scavenging of Reactive Oxygen Species by Silibinin dihemisuccinate", 《BIOCHEMICAL PHARMACOLOGY》, vol. 48, no. 4, 31 December 1994 (1994-12-31), pages 753 - 759 * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110183431A (en) * | 2018-06-09 | 2019-08-30 | 江苏新元素医药科技有限公司 | One kind is for liver disease or the compound of prevention |
| WO2019233440A1 (en) * | 2018-06-09 | 2019-12-12 | 江苏新元素医药科技有限公司 | Compound for treatment or prevention of liver diseases |
| JP2021527069A (en) * | 2018-06-09 | 2021-10-11 | 江▲蘇▼新元素医▲薬▼科技有限公司Ｊｉａｎｇｓｕ Ａｔｏｍ Ｂｉｏｓｃｉｅｎｃｅ Ａｎｄ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． | Compounds for the treatment or prevention of liver disease |
| JP7214247B2 (en) | 2018-06-09 | 2023-01-30 | 江▲蘇▼新元素医▲薬▼科技有限公司 | COMPOUNDS FOR THE TREATMENT OR PREVENTION OF LIVER DISEASE |
| CN110183431B (en) * | 2018-06-09 | 2023-04-11 | 江苏新元素医药科技有限公司 | Compound for treating or preventing liver diseases |
| CN109580818A (en) * | 2018-12-14 | 2019-04-05 | 江西省农业科学院农产品质量安全与标准研究所 | A method of Florfenicol drug residue in detection pig hair |
| CN109580818B (en) * | 2018-12-14 | 2022-04-08 | 江西省农业科学院农产品质量安全与标准研究所 | Method for detecting florfenicol drug residue in pig hair |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103113359B (en) | 2016-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7384920B2 (en) | Use of stilbene compounds in the manufacture of medicament for the prevention and treatment of diabetes or retrovirus-associated diseases | |
| WO2017162108A1 (en) | Pillararene complex, preparation method, pharmaceutical composition and use thereof | |
| WO2013060258A1 (en) | Clavatine a-c, preparation method thereof and pharmaceutical composition and use thereof | |
| CN102344481A (en) | Derivatives of 3-O-caffeoyloleanane type pentacyclic triterpene, preparation method thereof and application thereof | |
| CN103239493A (en) | Pharmaceutical composition for reducing blood sugar and preparation method thereof | |
| CN103113359B (en) | Silybin bis-bias succinate and pharmaceutical salts thereof | |
| CN103360456A (en) | Triterpenoid compounds, and preparation and application thereof | |
| CN101926844B (en) | Stellera chamaejasme L extract and anti-tumor action thereof | |
| CN103006769A (en) | Traditional Chinese medicine composition for treating cardiovascular and cerebrovascular diseases and preparation method thereof | |
| CN1965873A (en) | Chinese medicinal extract having blood sugar-lowering activity, its preparation process, composition and use | |
| CN103172622B (en) | The active isomer of silybin bis-bias succinate | |
| de Oliveira Penido et al. | Antischistosomal activity of aminoalkanethiols, aminoalkanethiosulfuric acids and the corresponding disulfides | |
| US20220296615A1 (en) | Combination product containing limonoid compound and sulfonylurea compound | |
| CN103193768B (en) | The silybin bis-bias succinate isomer for the treatment of hepatopathy | |
| CN108078989B (en) | Pharmaceutical composition for treating malaria | |
| CN110327356A (en) | Combination product comprising limonoid and alpha-glucosidase inhibitor | |
| CN103340880B (en) | Application of 2,3-dihydroxy benzoic acid ester compound in preparation of foods and medicines for treating diabetes | |
| CN107913273B (en) | The application of mesaconine | |
| CN101851162B (en) | Novel salvianolic acid compound L and preparation method and application thereof | |
| JP7383125B2 (en) | Combination products containing limonoid compounds and thiazolidinedione compounds | |
| WO2021208080A1 (en) | Use of ovatodiolide against novel coronavirus | |
| CN105348222B (en) | Compound PAC-1 or its salt and the pharmaceutical composition comprising them | |
| CN110327355A (en) | Combination product comprising limonoid and SGLT-2 inhibitor | |
| US7495024B2 (en) | Phenylalkyl N-hydroxyureas for combating atherosclerotic plaque | |
| CN108403980A (en) | A kind of hypoglycemic plant extracts active component and its preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address | ||
| CP03 | Change of name, title or address |
Address after: 710404 No. 4 Jicai South Road, Jixian Industrial Park, Zhouzhi County, Xi'an City, Shaanxi Province Patentee after: XI'AN ANJIAN PHARMACEUTICAL Co.,Ltd. Country or region after: China Address before: 710400 No.1 Yaochang Road, Zhouzhi County, Xi'an City, Shaanxi Province Patentee before: XI'AN ANJIAN PHARMACEUTICAL Co.,Ltd. Country or region before: China |